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ABSTRACT 
EXPRESSION, PURIFICATION AND CHARACTERIZATION OF HEPATITIS C 
VIRUS CORE PROTEIN FROM E.COLI USING A CHEMICALLY 
SYNTHESIZED GENE (1); AND CLONING, EXPRESSION, PURIFICATION 
AND CHARACTERIZATION OF THE MAJOR CORE PROTEIN (P26) FROM 
EQUINE INFECTIOUS ANAEMIA VIRUS (2) 
By Ashley James Birkett, Ph.D. 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy at 
Virginia Commonwealth University. 
Virginia Commonwealth University, 1994. 
Major Director: Darrell L. Peterson, Ph.D. 
Professor of Biochemistry. 
Department of Biochemistry and 
Molecular Biophysics. 
The hepatitis c virus (HCV) core gene has been chemically 
synthesized and used to direct the expression of core protein 
in Escherichia coli (E.coli). When cloned downstream of the 
inducible T7 promotor the core gene directed the expression of 
a soluble protein with a molecular weight of 22 kDa. Under 
native conditions the protein behaved in a manner consistent 
with the formation of a multimeric structure, which may 
represent assembled core particles. Further, when examined by 
electron microscopy a heterogeneous mixture of nucleocapsid-
like particles were visible. Core protein was specifically 
XV 
recognized by antibodies present in HCV infected serum, 
suggesting that this protein may be useful as a diagnostic 
tool for detecting HCV infection. To circumvent the 
difficulty in purifying this protein in significant quantities 
a core-polyhistidine fusion gene was constructed. This 
protein was 
chromatography, 
readily purified, using nickel 
under denaturing conditions. 
chelation 
Studies are 
currently on-going to ascertain the conditions required for 
refolding this protein, and the suitability of this protein to 
serve as a diagnostic tool. 
In a second study, the major core protein (p26) of the 
lentivirus equine infectious anaemia (EIAV) was expressed in 
E.coli and purified to >95% homogeneity. Circular dichroism 
spectroscopy revealed that p26 exhibits the following 
assignment of secondary structural elements; 40% alpha helix, 
22% beta sheet, 10% beta turn, and 28% random coil. It has 
been determined that p26 contains a single free cysteine 
residue (Cys48), and an intramolecular disulfide bond between 
cysteine residues 198 and 213. Data acquired by circular 
dichroism spectroscopy and fluorescence spectroscopy indicate 
that this disulfide bond plays a critical role in maintaining 
the structure of p26. Crystals of p26 were successfully grown 
at a protein concentration of 8mgjml in 0.1M cacodylate, 0.7M 
sodium acetate, pH 6.5, at 4 °C. A sandwich ELISA was 
developed, using recombinant p26, to detect anti-p26 
xvi 
antibodies in horse sera. The assay successfully identified 
the 19 positive sera in a blind panel of 30 samples supplied 
by the National Veterinary Service Labs (Ames, Iowa). 
Accordingly, the assay appears to meet the criteria required 
of a commercial diagnostic reagent for determining EIAV 
infection in horses. 
I. EXPRESSION, PURIFICATION AND CHARACTERIZATION 
OF HEPATITIS C VffiUS CORE PROTEIN FROM E.COLI 
USING A CHEMICALLY SYNTHESIZED GENE 
INTRODUCTION 
Hepatitis C Virus 
Hepatitis C virus (HCV) was identified in 1989 by 
researchers at Chiron as being the major cause of post­
transfusion non-A, non-B hepatitis {PT-NANBH) (Chao et al., 
1989). This ended a 15 years search for an ellusive virus 
that, in the late 1970's and early 1980's, reportedly infected 
up to 10% of the nation's blood supply (Aach et al., 1981). 
A 1990 report suggested that 60 to >90% of PT-NANBH observed 
in the u.s., Europe and Japan was caused by hepatitis C (Chao 
et al., 1990), which amounts to as many as 0.3 million cases 
per annum in the u.s. alone (Davis et al., 1990). The recent 
development of reliable diagnostic assays has effectively 
eradicated hepatitis c from the nation's blood supply; 
however, the virus continues to be transmitted by other 
routes such as intravenous drug use and sexual contact. 
Acute HCV infections are typically asymptomatic and 
generally less severe than those caused by either hepatitis A 
{HAV) or hepatitis B virus (HBV). However, it is the fact 
that approximately three-quarters of infections progress to a 
chronic state which has caused such a health concern. Chronic 
1 
2 
infections of HCV appear to persist for over 30 years, and are 
associated with the development of hepatocellular carcinoma 
(Colombo et al., 1989; Saito et al., 1990; Nishioka et al., 
1991; Ohkoshi et al., 1990). 
Genomic organization 
Hepatitis C virus is an enveloped virus with a diameter 
of 30-60nm and has a positive strand RNA genome. Several 
reports have highlighted the similarity, in terms of both 
sequence and genomic organization, of this virus to two 
families of viruses - the pestiviruses and the flaviviruses 
(Miller and Purcell, 1990). The latter are a family of small 
animal viruses which are categorized according to their 
homology to the yellow fever virus (flavus meaning 'yellow' in 
latin) , the prototype family member which was first described 
almost one century ago. This group of viruses now contains 
over 50 animal viruses, all of which have a single-stranded, 
positive RNA genome (for a review, see Chambers et al., 1990). 
The genome, which is typically 10-11kB in length, is 
transcribed directly into a single, genomic length mRNA. The 
mRNA is subsequently translated into a single polyprotein of 
approximately 3000 amino acids, which is processed by 
proteases to yield functional viral proteins. 
The hepatitis C viral genome has a coding region which 
is flanked by both 5' and 3' untranslated regions (UTR). The 
5' UTR is 341bp long and highly conserved, suggesting that it 
3 
Figure 1: Schematic Representation of the BCV Genome. 
4 
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may perform an as yet undefined regulatory function. The 
shorter 3' UTR (23-54bp) is less conserved and it's putative 
role in the lifecycle of the virus has not yet been 
identified. The coding sequence of the viral genome is 
translated into either a 3010 or 3011 amino acid polyprotein, 
which is processed by both cellular and viral proteases to 
generate mature or functional viral proteins (Figure 1) . 
The hepatitis C viral proteins have been categorized into 
two groups; the structural proteins (core, c; and envelope, 
E1 and E2/NS1), and the non-structural proteins {NS2-5). The 
structural proteins are derived from the amino terminus of the 
viral polyprotein and form the basic framework of the virus, 
whereas the non-structural proteins are derived from the 
carboxyl-terminus and exhibit various enzymatic activities 
which are involved in virus maturation and replication. 
Non-Structural Proteins 
The most intensely studied of the non-structural proteins 
to date has been NS3, which has recently been shown to possess 
serine protease activity {Tomei et al., 1993; Bartenschlager 
et al., 1993). NS3 specifically cleaves the viral precursor 
at dibasic amino acid sequences. This viral protease contains 
a 'catalytic triad' of amino acids (histidine, serine and 
aspartic acid), a motif which is characteristic of serine 
proteases. The essential function of these three amino acids 
is highlighted by the fact that they are conserved in all 
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viral isolates sequenced to date, and mutation of the 
catalytic serine residue (to alanine), has been shown to 
abolish enzymatic activity (Tomei et al., 1993; Bartenschlager 
et al., 1993). Since the function of this enzyme is to cleave 
the non-structural proteins of the viral polyprotein, an 
essential feature of the viral lifecycle, NS3 has been 
identified as a potential target of anti-viral therapy. 
Further, this 69kDa protein also possesses a nucleoside 
triphosphate binding domain which is speculated to be involved 
in a helicase activity (Takamizawa et al., 1991). 
Non-structural-5 protein is a 116kDa protein which is 
postulated to be involved in viral replication. It contains a 
'GDD' consensus sequence which is conserved among RNA 
dependent, RNA polymerases (Takamizawa et al., 1991). Recently 
it has been reported that NS5 codes for two distinct proteins, 
termed A and B, with molecular weights of 56 and 65 kDa (Tomei 
et al., 1993). The individual functions of these two proteins 
is still unclear at this time. 
NS2 and NS4 are very hydrophobic proteins with molecular 
weights of 24 and 53kDa respectively. Their hydrophobicity has 
led to the prediction that they serve a function which 
requires them to be 'membrane bound', although this has not 
been substantiated by experimental data. Like NS5, NS4 has 
recently been shown to be processed to yield two proteins of 
6 and 26 kDa (Tomei et al., 1993). 
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Structural Proteins 
There are now recognized to be 3 different structural 
proteins associated with the hepatitis C virus; core (C), and 
two envelope proteins (E1, and E2/NS1). Both of the envelope 
proteins are glycosylated. 
While the non-structural proteins of HCV are processed by 
NS3, the virally encoded serine protease, the structural 
proteins appear to be processed by proteases which are 
endogenous to the host. The cleavage of core and E1-E2/NS1 
was postulated to be mediated by a signal peptidase located in 
the lumen of the endoplasmic reticulum (ER) (Hijikata et al., 
1991), and this has recently been supported by experimental 
data ( Santolini et al., 1994) • Accordingly, the signal 
sequence for E1 is presumed to be located at the carboxyl­
terminus of core. Processed core protein is predicted to be 
191 amino acids in length (21-22kDa), and a species of 
approximately this size has been identified by immunoblotting 
following expression of the viral genome in a variety of 
eukaryotic expression systems (Chiba et al., 1991; Grakoui 
et al., 1993; Harada et al., 1991; Hijikada et al., 1991; 
Kumar et al., 1992). 
Diagnosing HCV Infection 
In just a few years rapid advancements have been made in 
curtailing the spread of this virus. This is largely as a 
result of the determination of the sequence of the viral 
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genome, which enabled the development of reliable assays for 
screening donated blood products. The effectiveness of these 
diagnostic assays has steadily increased since the 
introduction of the original c-100-3 assay. This assay was 
introduced in 1989 and screened for antibodies to a non­
structural region of the virus (Kuo et al., 1989). Current 
diagnostic assays detect antibodies to several structural and 
non-structural proteins and are extremely effective in 
identifying infected individuals. 
The first diagnostic assay for detecting HCV infection 
arose from the first HCV DNA clone (5-1-1), which was extended 
to cover 363 viral amino acids and fused to superoxide 
dismutase (SOD) (Kuo et al., 1989). The introduction of this 
assay was revolutionary in it's ability to screen sera for the 
major causative agent of PT-NANBH when it became commercially 
available in 1990. However, it soon became apparent that 
antibodies to this region of the viral polyprotein were not 
universal in HCV infection. Most patients only developed 
anti-c-100-3 antibodies after being infected for several 
months, and a significant proportion of patients, around 25%, 
failed to develop a humoral response to this antigen (Chiba et 
al., 1991; Harada et al., 1991). False positives were also 
a problem with this assay, particularly among individuals with 
alcoholic liver disease and autoimmune chronic active 
hepatitis (McFarlane et al., 1990). 
Once the entire HCV genome had been sequenced and 
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tentatively characterized it was determined that the viral 
sequence contained within the c-100-3 clone was derived from 
NS4, a relatively non-immunogenic protein. In recent years the 
inclusion of viral epitopes derived from the core and NS3 
regions of the viral polyprotein has markedly improved the 
sensitivity and specificity of HCV diagnostic tests. One of 
the most widely used diagnostic assay at present is an 
immunoblot assay known as RIBA-2, a test which incorporates 
four recombinant proteins; 5-1-1, c-100-3, C33c and c22. C33c 
is an NS3 fusion protein, and c22 is a core fusion protein. 
Patients with antibodies to just one of the four viral 
antigens are considered 'indeterminate' for hepatitis c 
infection, while those reacting to two or more are considered 
positive. Since the viral epitopes are fused to superoxide 
dismutase (SOD), an SOD control is included in the test to 
confirm that the reactivities detected are indeed specific for 
the viral sequences. 
The inclusion of NS3 and core epitopes in the second 
generation HCV diagnostic assays has greatly increased their 
sensitivity to the acute phase of hepatitis C infection (Puoit 
et al., 1992; Van der Peel et al., 1991). In addition to 
appearing earlier in infection than antibodies to c-100-3, 
antibodies to NS3 and core are also detected in patients 
suffering from NANBH who had previously tested negative for 
HCV infection. 
Various diagnostic ELISA's are also available for 
diagnosing HCV infection (Chemello et 
incorporate the same viral antigens 
al. , 1993) . 
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They 
as the recombinant 
irnrnunoblot assays, and, while they are easier to perform, they 
are unable to characterize antibody responses to individual 
proteins. 
Confirmation of the presence of viral nucleic acid in 
sera has traditionally been determined by hybridization using 
northern blots. However, the hepatitis c virus circulates at 
such low levels in the serum that this technique is not 
sensitive enough when considering infection with this virus 
(Alter and Hoofnagle, 1984). A combined reverse transcription 
and polymerase chain reaction (RT-PCR) has been employed 
successfully for detecting infection by the hepatitis c virus 
(Cristiano et al., 1991; Schlauder et al., 1992). Since 10% 
of patients with NANBH are negative for all HCV antibodies 
currently detected by RIBA-2 (Chemello et al., 1993), PCR 
provides an alternative method for detecting infection. Viral 
RNA is usually detectable 1-3 weeks after the patient presents 
symptoms of infection (Puoti et al., 1992). Further, since 
PCR detects the presence of viral RNA instead of antibodies to 
viral proteins, it is an excellent method for detecting an 
active HCV infection. Accordingly, PCR is typically used to 
evaluate the success of interferon therapy, in addition to 
differentiating between an active and a past-resolved 
infection. In a small group of patients where no antibody 
responses are detectable, RT-PCR is the only marker of 
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infection. 
In the RT-PCR test oligonucleotide primers are selected 
to coincide with highly conserved regions of the viral genome, 
typically the 5' UTR {Imberti et al., 1991). The inherent 
sensitivity of this procedure, which is one of its advantages, 
is also one of it's shortfalls since cross-contamination of 
samples is a major concern. Nevertheless, despite fears of 
contamination, as well as its high expense, RT-PCR has proved 
to be an important tool for detecting HCV infection. 
Vaccines and Therapy For HCV Infection 
Although there is not a commercially available vaccine 
for hepatitis C at the present time, trials using recombinant 
envelope proteins {gp33 and gp72), conducted in chimpanzees, 
are underway. In the only trial published to date, five of 
seven chimpanzees 'immunized' with E1 and E2 exhibited 
protection when challenged with the same viral subtype {Choo 
et al., 1994). 
Therapy for hepatitis C virus infection has largely 
focussed on alpha-interferon, which has been somewhat 
successful in treating chronically infected patients (Davis et 
al., 1989; DiBisceglie et al., 1989). During interferon 
therapy patients exhibit a decrease in the levels of liver 
enzymes circulating in the serum, signifying a decrease in 
the amount of liver damage being inflicted. However, around 
70% of patients relapse shortly after the cessation of 
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administration of the drug. 
While studies are ongoing in evaluating the usefulness 
of interferon therapy, it is becoming evident that other 
factors, in addition to the typical parameters such as patient 
profile and treatment schedule, play a role in the 
effectiveness of this treatment. An interesting finding, 
particularly from a biochemical viewpoint, is that the 
genotype of the virus may play an important role in affecting 
the outcome of interferon therapy (Tsubota et al., 1993). 
This raises an intriguing question concerning the relationship 
between clearance of the virus and the immune responsiveness 
to different B and T-cell sites, since it would appear that 
certain genotypes of the hepatitis C virus are more resistant 
to an immune system which has been 'boosted' by interferon 
treatment than others. 
Viral Subtypes 
Four different HCV genotypes (I, II, III and IV) have 
been categorized to date. Genotypes I and II are classified as 
subtype 1, and genotypes III and IV are classified as subtype 
2 (Machida et al., 1992). The majority of amino acid 
variation between these genotypes is clustered around two 
hypervariable regions (HVR's) located in the envelope 
sequences. HVR-1 covers amino acids 1-25 of E2/NS1, and HVR-2 
spans amino acids 91-99 of E2/NS1 (Okada et al., 1992). 
A clinical study published in 1992 presented evidence 
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that patients are more likely to respond to interferon therapy 
if they are infected with a single viral isolate than if they 
are infected with multiple viral genotypes (Okada et al., 
1992). This observation reaffirms the fact that there is 
indeed a differential viral sensitivity to interferon 
treatment. It has also been shown that the 27 amino acid 
stretch that encompasses HVR-1 mutates at a rate of 
approximately 1 amino acid per month, and that the newest 
mutant soon becomes the predominant genotype present in the 
host (Kato et al., 1992). This is presumably due to the 
capability of the 'new mutant' to evade the immune system of 
the host, at least temporarily. 
Properties of Hepatitis C Virus Core Protein 
Structure and Function 
HCV core protein has been successfully expressed in 
several eukaryotic systems, including baculovirus (Hsu et al. , 
1993), and monkey cos cells (Harada et al., 1991); as well as 
in vitro, using a rabbit reticulocyte lysate (Hijikata et al., 
1991). The benefit of these systems is that they are capable 
of processing the structural polyprotein 
manner to that seen during infection. 
in an analogous 
These studies 
permitted the mapping of the amino terminus of core protein to 
the 5' end of the viral genome, directly after the 5' UTR. 
Further, the carboxyl-terminus of core was mapped by 
sequencing the amino terminus of E1, which is cleaved from 
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core during polyprotein maturation in the endoplasmic 
reticulum. Accordingly, core protein has been postulated to 
be 191 amino acids in length (Takeuchi et al., 1990), assuming 
that cleavage from E1 involves a single proteolytic cleavage 
event. However, it is conceivable that core and E could be 
cleaved by the excision of a short 5-10 amino acid peptide, 
which would still generate core protein exhibiting an apparent 
molecular weight of approximately 21kDa. 
Consistent with computer aided predictions, core protein 
does not appear to undergo any post-translational 
modifications such as glycosylation (Harada et al., 1991; Hsu 
et al., 1993). This observation has prompted the suggestion 
that core protein could be expressed effectively in a 
prokaryotic system such as E. coli, and may have antigenic 
properties similar to those of the protein expressed in 
baculovirus (Chiba et al., 1991). Indeed, a single report 
has described the successful expression of core protein in 
E. coli (Muraiso et al., 1990). This protein was shown to 
react specifically with antibodies from HCV infected 
individuals by immunoblotting. 
Despite the successful expression of core protein, using 
several different expression systems, the protein has not been 
purified in sufficient quantities to permit it's structure and 
functional characteristics to be examined. 
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Immunogenicity 
Unlike the envelope sequences, the core sequences of 
hepatitis c virus are remarkably well conserved. While the 
envelope sequence undergoes a rapid mutation, particularly at 
the HVR's, the core protein does not. It is widely accepted 
that there are only two different core sequences; the 
first, found in subtype 1, and the second associated with 
subtype 2. The major site of variability has been mapped to 
a region near the middle of the 22kDa protein, where the two 
subtypes differ by 7 amino acids over a stretch that spans 
just 11 in total (Figure 2). 
B-cell epitopes within the core protein sequence have 
been tentatively mapped using both synthetic peptides and 
fusion proteins. Using GST-core fusion proteins, the major 
B-cell epitope(s) was mapped to the region encompassing amino 
acids 21-41 of core (Nasoff et al., 1991). Similarly, 
residues 39-74 have been implicated in harboring a B-cell 
epitope using synthetic peptides (Okamoto et al., 1990). 
Recently Feinstone and co-workers have more precisely mapped 
the amino-terminal epitope to amino acids 33-50 (Akatsuka et 
al., 1993). In combination, these data suggest that the amino­
terminal B-cell epitope, if it is indeed a single epitope, is 
located within a 9 amino acid sequence between amino acids 33-
41. The same group has successfully identified two further B-
cell sites on core. These epi topes, which have only been 
observed using synthetic peptides (Nasoff et al., 1991), have 
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been mapped to amino acids 165-174 (Akatsuka et al., 1993). 
It has recently been reported that core possesses two HLA 
class-1 restricted epitopes (Kozeil et al., 1993). These 
sequences are situated at the amino-terminal region of the 
protein, and their presence indicates that core protein is a 
target for HCV-specific cytotoxic T lymphocytes. These cells 
are an integral part of the immune system, and are recognized 
as having particular importance in destroying virally infected 
cells. 
Core Protein in Diagnosing HCV Infection 
The successful cloning and expression of core protein, in 
a variety of different expression systems, prompted the study 
of humoral responses to this protein using immunoblots. A 
study published in 1991 used core protein expressed in 
baculovirus to develop an ELISA to measure anti-core 
antibodies in two hepatitis C patients (Chiba et al., 1991). 
The first patient showed a typical clinical course of chronic 
NANBH exhibiting multiple peaks of ALT, a marker of liver cell 
damage caused by hepatitis (Figure 3A). It was determined 
that anti-core antibodies were detectable 7 weeks post­
infection in this particular patient, which was before the 
first peak of ALT. Alternatively, anti-c-100-3 antibodies 
were not detectable until 57 weeks post-infection, almost a 
full year after the anti-core activity was detectable. 
IPKARRPEGRTWAQPGY Subtype 1 (Genotypes I and II) 
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Figure 2: Amino Acid Subtype Differences in core. 
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In the second patient, who also exhibited a typical, yet 
different, clinical course of NANBH, the results were similar 
-anti-core antibodies were detected at about 10 weeks post­
infection (Figure 3B). This was just after the elevation in 
the serum ALT levels, but before the single ALT peak 
exhibited by this patient. Despite maintaining low, but 
nevertheless abnormal levels of ALT for 4 years, the 
patient remained anti-c-100-3 negative (Chiba et al., 1991). 
Examination of 23 other NANBH patients showed that while 
13 patients seroconverted to anti-core positive within 1-3 
months, only 4 patients seroconverted to anti-c-100-3 positive 
during the same period. 
These results highlight the usefulness of core protein as 
a diagnostic tool for detecting HCV infection. Predictably, 
the inclusion of core epitopes in the commercially available 
diagnostic assays has dramatically increased their 
effectiveness, not only for detecting infection at an earlier 
stage, but also detecting infection in patients who did not 
develop anti-c-100-3 antibodies. Further, it has been 
suggested that detecting infection at an earlier stage is 
beneficial for interferon therapy. Those patients receiving 
interferon treatment in the acute stage of infection are more 
likely to clear the virus before it progresses to a chronic 
infection (Davis et al., 1989; Di Bisceglie et al., 1989). 
The ideal method for detecting anti-core antibodies would 
be with an ELISA assay, where recombinant core protein would 
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Figure 3: Detection of Anti-p22 in Hepatitis C Patients. The 
first case (a) shows a typical course of chronic hepatitis C 
with multiple peaks of ALT. The second case (b) showed another 
typical course of chronic hepatitis C, having a single ALT 
peak but maintaining low but significant abnormal ALT value 
for years. ALT levels and anti-cl00-3 levels are shown in 
Karmen units (KU) and cpm in a radioimmunoassay, respectively. 
Anti-p22 activity is shown as a percentage of the positive 
control to minimize the difference of A.10 values in different 
plates. The positive control sample was from donor blood that 
was positive for anti-cl00-3 and induced hepatitis C in the 
patient. (Reproduced from Cbiba et al., 1991) 
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be used to capture antibodies. Ideally, this recombinant 
antigen would mimic the protein expressed during HCV 
infection, ensuring maximum recognition by circulating 
antibodies. A source of recombinant core protein would also 
permit structural studies of the protein. 
SPECIFIC AIMS 
1. Chemically synthesize the hepatitis c core gene using 
overlapping synthetic oligonucleotides. 
2. Express hepatitis C core protein using an E.coli expression 
system and develop a purification protocol for the protein. 
3. Study the structural and immunological characteristics of 
the purified protein. 
BACKGROUND 
Chemical Gene Synthesis 
The chemical synthesis of DNA, in the form of single 
stranded oligonucleotides, has enabled complete genes to be 
synthesized in an entirely chemical manner. This procedure has 
many potential applications, the most obvious being the 
synthesis of genes when a eDNA template is unattainable. 
Further, the recent acknowledgement of the problem caused by 
differential codon usage between species in the overexpression 
of cloned genes means that genes can now be tailor made to 
suit the codon usage frequency of the species in which the 
gene is to be expressed, instead of the one from which it is 
derived. A future application of chemical gene synthesis may 
be the synthesis of novel genes to direct the expression of 
man-made proteins or peptides exhibiting novel enzymatic or 
functional activities. 
Currently there are two procedures for chemically 
synthesizing genes. The first requires the chemical synthesis 
of the entire gene, i.e. both strands. In this procedure the 
oligonucleotides are first annealed, and then nicks are 
repaired by treatment with DNA ligase (Agarwai et al., 1970; 
22 
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Khorana, 1979). This product can then be cloned directly, or 
amplified by PCR prior to cloning. 
The alternate procedure is likely to be more cost 
effective as it does not involve complete chemical synthesis 
of the gene. Instead, pairs of overlapping oligonucleotides 
are annealed, and then filled-in, using DNA polymerase, to 
generate a double stranded gene fragment which can be cloned 
(Rossi et al., 1982; Scapulla et al., 1982). This procedure is 
less dependent upon the secondary structure of the 
oligonucleotides, and is generally considered to be more 
efficient. Current technologies dictate that the maximum 
fragment length that can be generated is approximately 200bp, 
since the present upper limit for oligonucleotide synthesis is 
around 100bp. Therefore, if the final gene product is greater 
than 200bp, gene fragments must be connected by restriction 
sites so that they can be assembled into a final, full-length 
product. While this does impose some degree of inflexibility 
to the procedure, the degenerate nature of the genetic code, 
tied to the fact that there are an ever increasing number of 
restriction enzymes/sites from which to choose, means that 
this is unlikely to be an unsurmountable problem. 
After careful assessment of each procedure it was decided 
that the second procedure, where overlapping oligonucleotides 
are filled in using polymerase, would be implemented for the 
chemical synthesis of the hepatitis C core gene. 
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Redesigning of the HCV Core Gene to Facilitate it's Chemical 
Synthesis 
Minor alterations were made to the core sequence, subtype 
1, to facilitate its chemical synthesis and successful 
expression in E. coli. Firstly the nucleotide sequence was 
modified at six sites in order to create new and unique 
restriction sites. This facilitated the synthesis of the gene 
as five independent fragments, of between 70 and 150 base 
pairs in length, connected by restriction sites. The 
alterations in the nucleotide sequence were achieved with 
only a single change in amino acid sequence, a glycine 
replacing serine at residue 2. This change was necessary in 
order to introduce an Nco! restriction site at the 5' end of 
the gene for cloning purposes. A termination codon was 
introduced at the predicted 3' end of the gene after the final 
residue, Cys184. This was necessary since the viral genome is 
translated as a single polyprotein in vivo and therefore does 
not contain a termination codon at the 3' end of the core 
gene. Amino acid codons were selected based upon the 
frequency of usage in E.coli, since this would be the species 
in which expression of the protein would be carried out. Care 
was taken to avoid the inclusion of codons which are used only 
rarely by E.coli, as it has been widely reported that such 
'rare codons' often obviate high level expression of exogenous 
genes . 
The restriction sites which were used to connect the five 
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Fiqure 4: Nucleotide and Amino Acid Sequences of the Synthetic 
HCV Core Gene. The six 'engineered' restriction sites are 
shown in bold type. 
N 
c 
0 
I 
ccatgggcacgaatcctaaacctcaaagaaaaaccaaacgtaacaccaaccgccgcccac 
1 ---------+---------+---------+---------+---------+---------+ 60 
ggtacccgtgtttaggatttggagtttctttttggtttgcattgtggttggcggcgggtg 
M G T N P K P Q R K T K R N T N R R P Q 
aggacgtcaagttcccgggcggtggtcagatcgttggtggagtttacctgttgccgcgca 
61 ---------+---------+---------+---------+---------+---------+ 120 
tcctgcagttcaagggcccgccaccagtctagcaaccacctcaaatggacaacggcgcgt 
D V K F P G G G Q I V G G V Y L L P R R 
s 
a 
c 
I 
ggggccctagattgggtgtgcgagctccgaggaagacttccgagcggtcgcaacctcgtg 
121 ---------+---------+---------+---------+---------+---------+ 180 
ccccgggatctaacccacacgctcgaggctccttctgaaggctcgccagcgttggagcac 
G P R L G V R A P R K T S E R S Q P R G 
gtagacgtcagcctatccccaaggcacgtcggcccgagggcagaacctgggctcagcccg 
181 ---------+---------+---------+---------+---------+---------+ 240 
catctgcagtcggataggggttccgtgcagccgggctcccgtcttggacccgagtcgggc 
R R Q P I P K A R R P E G R T W A Q P G 
K 
p 
n 
I 
ggtacccttggcccctctatggcaatgagggctgcgggtgggcgggatggctcctgtctc 
241 ---------+---------+---------+---------+---------+---------+ 300 
ccatgggaaccggggagataccgttactcccgacgcccacccgccctaccgaggacagag 
Y P W P L Y G N E G C G W A G W L L S P 
B 
a 
m 
H 
I 
cccgtggatctcggcctagctggggccccacggatccccggcgtaggtcgcgcaatttgg 
301 ---------+---------+---------+---------+---------+---------+ 360 
gggcacctagagccggatcgaccccggggtgcctaggggccgcatccagcgcgttaaacc 
R G S R P S W G P T D P R R R S R N L G 
26 
gtaaggtcatcgatacccttacgtgcggcttcgccgacctcatggggtacataccgctcg 
361 ---------+---------+---------+---------+---------+---------+ 420 
cattccagtagctatgggaatgcacgccgaagcggctggagtaccccatgtatggcgagc 
K V I D T L T C G F A D L M G Y I P L V 
X 
b 
a 
I 
tcggcgctcctcttggaggagctgccagggccctggcgcacggcgtccgggttctagaag 
421 ---------+---------+---------+---------+---------+---------+ 480 
agccgcgaggagaacctcctcgacggtcccgggaccgcgtgccgcaggcccaagatcttc 
G A P L G G A A R A L A H G V R V L E D 
acggcgtgaactatgcaacagggaaccttcctggttgctctttctctatcttccttctgg 
481 ---------+---------+---------+---------+---------+---------+ 540 
tgccgcacttgatacgttgtcccttggaaggaccaacgagaaagagatagaaggaagacc 
G V N Y A T G N L P G C S F S I F L L A 
H 
i 
n 
c 
I 
I 
ccctgctctcttgttaac 
541 ---------+-------- 558 
gggacgagagaacaattg 
L L S C * 
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Piqure 5: Nucleotide Sequence of the Pive Pairs of 
Oligonucleotides used to construct the synthetic BCV Core 
Gene. Oligonucleotides are written 5' to 3', and the regions 
of overlap within pairs are indicated by bold type. 
Primer la 
ccatgggcacgaatcctaaacctcaaagaaaaaccaaacgtaacaccaaccgccg 
cccacaggacgtcaagttcccgggcggtgg 
Primer lb 
gagctcgccacacccaatctagggcccctgcgcggcaacaggtaaactccaccaa 
cgatctgaccaccgcccgggaacttgac 
Primer 2a 
gagctccgaggaagacttccgagcggtcgcaacctcgtggtagacgtcagcctat 
ccccaaggca 
Primer 2b 
ggtacccgggctgagcccaggttctgccctcgggccgacgtgccttggggatagg 
ctgac 
Primer Ja 
ggtacccttggcccctctatggcaatgagggctgcgggtgggcgggatgggcggg 
atggctc 
Primer lb 
ggatccgtggggccccagctaggccgagatccacggggagacaggagccatcccg 
cccacccgc 
Primer 4a 
ggatccccggcgtaggtcgcgcaatttgggtaaggtcatcgatacccttacgtg 
cggcttcgccgacctcatggggtacata 
Primer 4b 
tctagaacccggacgccgtgcgccagggccctggcagctcctccaagaggagcg 
ccgacgagcggtatgtaccccatgaggtcgg 
Primer Sa 
tctagaagacggcgtgaactatgcaacagggaaccttcctggttgctctttc 
Primer Sb 
gttaacaagagagcagggccagaaggaagatagagaaagagcaaccaggaaggt 
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Pigure 6: Cloning strategy for BCV core Gene Praqmenta. 
Panel A - Schematic representation of the 'annealing' and 
'filling-in' reaction for the synthesis of fragment 1 using 
oligonucleotides la and lb. Panel B - Nucleotide sequence and 
relevent restriction sites in the multiple cloning site of 
pUClSN to show the sites of insertion of each of the five DNA 
fragments. 
n 
A 
B 
N 
c 
0 
I 
ccatgggcacgaatcctaaacctcaaagaaaaaccaaacgtaacaccaaccgccgcccac 
<-----------------------------------------------------------
M G T N P K P Q R K T K R N T N R R P Q 
aggacgtcaagttcccgggcggtgg----------------------------------> 
I I I I I I I I I I I I I I I I I I I I 
I I I I I I I I I I I I I I I I I I I I 
<----cagttcaagggcccgccaccagtctagcaaccacctcaaatggacaacggcgcgt 
D V K F P G G G Q I V G G V Y L L P R R 
s 
a 
c 
I 
--------------------------> 
ccccgggatctaacccacacgctcgag 
G P R L G V R A 
1 2 3 
Sac! BarnHI 
4 5 
Hincii 
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ccatggttacgaattccgagctcggtacccggggatcctctagagtcgacctgcaggcatgcaagcttgg 
Nco! Kpni Xbai Hindi II 
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gene fragments were selected to correspond to sites in the 
multiple cloning site of pUC18N. This vector is essentially 
pUC18 except that it contains an Nco! restriction site 
immediately downstream of the multiple cloning site (Zheng 
et al., 1992). The order of the restriction sites made it 
possible to sequentially move down the pUC18N multiple 
cloning site and insert fragment 1, then fragment 2, and so on 
until all 5 fragments had been cloned. 
Predicted Features of HCV Core Protein 
Successful expression of the synthetic HCV core gene 
would yield a protein of 184 amino acids in length, and having 
a predicted molecular size of 20,600 Daltons. The amino acid 
sequence has no potential glycosylation sites. 
Probably the most striking feature of this protein is 
it's extreme basicity, which is predicted to be 11.94. The 
protein has 24 arginine residues (13%) and 7 lysine residues 
(3.8%), amounting to 31 basic residues out of a total of 184 
(16.8%). 
Expression of Viral Core Proteins in E. coli 
E. coli was selected for the expression of HCV core 
protein for several reasons. First and foremost viral core 
proteins are typically not glycosylated, or targets of other 
post-translational modification, rendering a Prokaryotic 
33 
system such as E.coli an ideal choice for expression. In 
addition to giving high levels of expression, E.coli is 
undoubtedly the best understood system for expression of 
exogenous genes, and the DNA manipulations involved in 
creating expression vectors are relatively simple. Further, 
the many different expression plasmids and cell strains 
provides a multitude of different expression systems. 
Finally, the culture media required for growing bacteria is 
relatively cheap, an important consideration when making large 
scale fermentations. 
Several viral core proteins have been successfully 
purified following their over-expression in E.coli. Notably 
the HBV core protein (Stahl et al., 1982) and HIV core protein 
(Ehrlich et al., 1992), both of which assemble into core 
particles. 
MATERIALS AND METHODS 
Chemical Synthesis of the HCV Core Gene 
Synthesis and Preparation of Oligonucleotides 
Oligonucleotides were synthesized by the 'MCV-VCU Nucleic 
Acid Core Facility'. To prepare the oligonucleotides for use, 
they were first 'de-blocked' by heating to 55°C, overnight (or 
85°C, for 1 hour), in tightly sealed tubes. The detritylated 
primers were then dried under vacuum, resuspended in lml of 
distilled water, and extracted three times with 0.5ml of ethyl 
ether. Finally the oligonucleotides were dried and 
resuspended in 0.6ml of distilled water. The concentration 
was determined by measuring the absorbance at 260nm, and 
dividing this figure by the extinction coefficient for the 
oligonucleotide (A=16, 000, G=12, 000, C=7, 000, T=9, 600 M"1cm·1) • 
Annealing, Filling-In, and PCR Amplification of Gene Fragments 
Ten oligonucleotide primers were synthesized as five 
pairs (Figure 5), where each pair corresponded to one fragment 
of the gene, and had a 20 base pair overlap at their 3' end 
such that they could be annealed. Once annealed, a pair of 
primers created a single fragment which stretched from one 
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restriction site to the next but was only double stranded in 
the middle where the 20 base pair overlaps had annealed. 
Following annealing at 42°C, for 2 minutes, the DNA was made 
double stranded by five cycles of 'filling-in' at 72°C for 30 
seconds, and 'melting' at 94°C for 1 minute. This does not 
achieve amplification of the DNA, but it does maximize the 
amount of full length, double stranded DNA produced (Figure 
6). The reaction volume was 100�1, and conditions for 
oligonucleotide extension were as follows: 250nM of each 
oligonucleotide, 400�M dNTP's, 1x Vent buffer, 1 unit Vent 
polymerase (all New England Biolabs). This strategy proved to 
be successful for the cloning of fragments 2,3 and 5. However, 
fragments 1 and 4 could not be cloned using this procedure. It 
was inferred that these two fragments, which incorporate 
longer oligonucleotides than fragments 2,3 and 5, possibly 
contained less full length product following the 'filling-in' 
step. To circumvent this possibility, pairs of short 
oligonucleotides (20-mers) which were complementary to the 3' 
ends of the filled-in fragment (Figure 7), were used to 
amplify the fragment prior to cloning. Because the 3' ends of 
the fragments are only present after successful primer 
extension, the PCR amplification was specific for full-length 
product. 2�1 of the fill-in reaction was used as the template 
for this PCR reaction. The reaction conditions were as 
follows: 400�M dNTP's, l�M of each 20-mer primer, 1 unit of 
Vent polymerase in 1x Vent buffer. 
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5' g gee atq qgc acg aat cct aaa cct (Fl-fwd, Nco!) 
5' egg age tcg cac ace caa cct gg (Fl-rev, Sac!) 
5' acq qat ccc egg cgt agg tc (F4-fwd, BamHI) 
5' ctt eta qaa ccc gga cgc cg (F4-rev, Xbal) 
Figure 7: Sequences of the Oligonucleotide Primers used to 
Amplify HCV Core Gene Fragments 1 and 4 (Fl and F4). 
Restriction sites are highlighted with bold type. 
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Cloning of Double Stranded Gene Fragments 
DNA was extracted directly from PCR reactions using a 
commercially available kit ('Mermaid', BI0101), digested 
with the appropriate pair of restriction enzymes (NEB), and 
cloned into the multiple cloning site of pUC18N. 'Mini-prep' 
plasmid isolations were performed using the alkaline lysis 
method (Sambrook et al., 1989), and plasmid stocks of positive 
clones were made using a commercially available plasmid 
isolation kit (Qiagen). 
DNA Sequencing 
The sequence of the final construct, pUC18N-C184, was 
confirmed by automated DNA sequencing performed by the 'MCV­
VCU Nucleic Acid Core Facility.' 
Expression and Purification of Core Protein 
Expression in E.coli 
The entire core gene was excised from pUC18N-C184 using 
the restriction enzymes Ncoi and Hindiii. This 570bp fragment 
was inserted into pET3d (Novagen) at the Ncoi/Hindiii sites, 
creating pET3d-HCVC (Figure 8). Digestion of pET3d with these 
enzymes excises the T7 terminator; however, this was expected 
to have a minimal effect on gene expression. The expression 
plasmid (pET3d-HCVC) was transformed into the E.coli strain 
aMS174(DE3) (Novagen) and grown at 37°C in M9 media (Sambrook 
et al., 1989) supplemented with 50�g/ml ampicillin. When the 
Hindi II 
pET3d-HCVC 
Figure 8: PET3d-HCVC expression plasmid. 
Hi nell 
Xbal 
Bam HI 
Kpnl 
Sac I 
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cell density reached an� of 0.6-0.8 the cells were induced 
by the addition of 0.4mM IPTG and grown for an additional 3 
hours. Cells were harvested by centrifugation at soooxg for 10 
minutes. Dry cell pellets were stored at -70°C until needed. 
Purification of Core Protein 
Cell pellets were suspended in one-tenth of the original 
culture volume of 50mM Na-phosphate, pH 6.8. The cells were 
lysed by a single passage through a french pressure cell, and 
centrifuged at 18, OOOxg for 30 minutes to pellet cellular 
debris. The soluble cell lysate was applied to a 
hydroxyapatite column which had been pre-equilibrated with 
10mM sodium phosphate, pH6. 8. The column was washed with 
150rnM sodium phosphate, pH 6.8, until the absorbance 
(280nm) of the eluent fell below 0.1. The protein was 
eluted from the column by washing with 250mM sodium phosphate, 
pH 6.8. The protein in this fraction was concentrated by 
precipitation with 25% polyethylene-glycol 8000 and 
recovered by centrifugation at 10,000xg for 30 minutes. 
The precipitate was resuspended in a minimal volume 
of 10mM tris-Cl, pH7.8, and subjected to gel filtration 
chromatography using a sepharose 4B column (Pharmacia) . 
Fractions were tested for core protein by immmunobotting with 
a monoclonal anti-core antibody (410G5H4). 
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SDS-PAGE 
Analytical polyacrylamide gel electrophoresis was 
performed according to the method of O'Farrell (O'Farrell, 
1975). 4% acrylamide stacking gel and 15% acrylamide 
resolving gel were employed. 
Characterization of Core Protein 
Ulrra-Violer Specrroscopy 
Ultra-violet spectroscopy was performed using a Hewlett 
Packard 8451A diode array spectrophotometer. 
Gel Filrrarion Chromarography 
Gel filtration was carried out using a 'Superose 6' 
column attached to a Pharmacia FPLC system. The buffer was 
10mM tris-Cl, pHB.O, and the flow rate was 0.4mljmin. 
Elecrron Microscopy 
Purified HCV core protein (2mgjml) was applied to the 
grid and negatively stained with 1% phosphotungstic acid. The 
protein was examined using a Philips EM400 elecrton microscope 
at a screen magnification of x 130,000. 
Immunological Studies of Core 
Wesrern Blorring 
Following the separation of protein samples on 15% sos-
PAGE gels, 
(Millipore) , 
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the protein was blotted onto PVDF membrane 
according to the method of Burnette (1981). 
Transfer was achieved using the following buffer composition; 
192mM glycine, 20% methanol, 1g/L SDS, 10mM tris-Cl, pH 8.5, 
for 1 hour at 200mA. Membranes were blocked in a 4% solution 
of BSA (Sigma) in PBS for 30 minutes. Next the membranes were 
incubated with an anti-core monoclonal antibody in PBS 
supplemented with 1% BSA overnight. The following morning 
membranes were washed and incubated with a 1:3000 dilution of 
rabbit anti-mouse peroxidase antibody (Sigma) for 1 hour. 
Finally, the membranes were washed extensively and developed 
using 8ml PBS, 2ml chloronapthol (Sigma) in methanol (3mg/ml), 
and 8�1 hydrogen peroxide (30%) (Fisher). 
Monoclonal Antibodies to HCV Core 
The two anti-core monoclonal antibodies (410G5H4 & 
46E7F6) were a gift from Ortho Diagnostics (Raritan, NJ). 
They were both raised against a synthetic peptide, 
corresponding to amino acids 29-43 of the HCV polyprotein, 
having the following sequence, QIVGGVYLLPRRGPR. 
Serology of HCV Positive Sera 
A series of well-characterized HCV positive serum 
samples were also a gift from Ortho Diagnostics. Serum 
samples 4384, GC2230792, and GC2230800 were reactive to all 4 
proteins (5-1-1, c100-3, c22-3 and c33c) on RIBA-2, sample 
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4523 was reactive to c33 and c22-3 only, and samples 12-080 
8906 and GJ61329 were reactive to c22-3 only. 
ELISA to Detect Anti-Core Antibodies 
Purified HCV core protein, coated to the wells of 
microtitre plates, was used in an ELISA to capture anti-core 
antibodies. The assay was tested with human serum, known to 
have anti-HCV core antibodies, and with two monoclonal 
antibodies in order to determine whether they could bind to 
core protein under native conditions. 
Plates were coated overnight at room temperature at a 
protein concentration of 25�gfml in bicarbonate buffer, pH 
9.2. Next morning the plates were blocked with washing buffer 
(1hr), dried, and stored at -20°C until needed. 
Monoclonal anti-core antibodies were serially diluted in 
dilution buffer (Ortho Diagnostics), and 50�1 of each dilution 
was added to the microtitre wells. Following a 30 minute 
incubation the wells were washed and 50�1 of a 1:3000 dilution 
of peroxidase conjugated anti-mouse antibody (Sigma) was added 
and incubated for 10 minutes. Following extensive washing, 
50�1 of TM Blue substrate (TSI) was added to each well and 
allowed to develop for 5 minutes. The reaction was stopped by 
the addition of 100�1 of 1N sulfuric acid and the plates were 
read at a wavelength 450nm. 
To detect human anti-core antibodies the procedure was 
similar to that described above, except for the following 
43 
points. Serum was diluted 200 and 1000-fold prior to testing, 
and an anti-human peroxidase conjugated antibody 
(1:3,500) (Ortho Diagnostics) was used to detect bound 
antibody. 
Construction of Plasm ids for the Expression of Histidine-Tagged Core 
Proteins 
In an attempt to develop a more rapid and reproducible 
purification procedure for hepatitis c core protein, a series 
of vectors which express core protein as a poly-histidine 
tagged protein were constructed. Specifically, the 'pQE' 
family of vectors (Qiagen) were tested for their ability to 
direct the expression of core protein. The polyhistidine (6x 
His) can be incorporated at either the amino or carboxyl­
terminus of proteins which, via the strong affinity of poly­
histidine sequences for nickel, permits rapid purification of 
proteins using nickel chelation chromatography (Hochuli, 
1990). 
Construction of pQE30-HCVC and pQE60-HCVC 
The plasmid pQE30 directs the high-level expression of 
cloned proteins, complete with an amino-terminal poly­
histidine affinity tag, in E.coli. To construct the plasmid 
pQE30-HCVC it was necessary to introduce a Bglii restriction 
site at the 5' end of the core gene; BamHI was not an 
alternative because the gene already contains an internal 
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BamHI restriction site (Figure 9). Bglii was chosen because 
it is complementary to BamHI, by virtue of their common 'over­
hang' sequence (GATC), and it is also located immediately 
downstream of the 6 histidine codons. Although a variety of 
other cloning sites were available, cloning into the BamHI 
site of the plasmid reduced the number of extraneous amino 
acids inserted between the histidine tag and the start of the 
core gene to just two (arginine and serine). The Hindiii site 
at the 3' end of the core gene in the original pUC18N-C184 
clone, which was used as the template for PCR, was 
suitable for the 3' end of the gene since pQE30 contains a 
Hindiii restriction site in it's multiple cloning site. 
Therefore, a perfect match M13 reverse sequencing primer was 
a suitable choice to serve as the reverse sequencing primer. 
While the plasmid pQE30 is suitable for constructing 
expression vectors which include an amino-terminal histidine 
tag, pQE60 allows the construction of expression vectors which 
insert a carboxyl-terminal tag onto cloned proteins 
(QiaExpressionist, 2nd Edition). To construct the plasmid 
pQE60-HCVC it was necessary to design a mismatch primer which 
removed the stop codon from the original clone, as well as 
insert an 'in-frame' Bglii restriction site at the 3' end of 
the gene. This allowed the poly-histidine codons to be read, 
'in-frame', directly after the gene. In this instance Bglii 
was chosen over BamHI for two reasons. Firstly, the presence 
of the aforementioned internal BamHI in the core gene, and 
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secondly, the insertion of the gene at the Bglii restriction 
site of the plasmid reduces the number of extraneous amino 
acids between the 3' end of the core gene and the six 
histidine cedens. Like pQE30-HCVC, it was not possible to 
avoid the insertion of an arginine and a serine between the 
core gene and the histidines. The Ncoi restriction site in 
pQE60 was used for insertion of the 5' end of the gene. Thus 
it was possible to use the 'perfect match' Ncoi primer used 
during the chemical synthesis of the core gene as the forward 
primer (Figure 7). 
Both modified HCV core genes were amplified using PCR, 
and cloned into their respective vectors. E.coli, strain M15, 
was used for all steps using pQE vectors. 
Construction of pET3d-HCVC(C-His} 
To construct this plasmid the HCV core gene, complete 
with it's carboxyl-terminal histidine tag, was excised from 
pQEGO-HCVC as an Ncoi-Hindiii fragment. This DNA was cloned 
directly into the plasmid pET3d, which had itself been 
prepared by digestion with the same two restriction enzymes. 
Construction of pET3d-HCVC(N-His} 
In order to construct this plasmid it was necessary to 
simultaneously introduce an Nco! restriction site upstream of 
the amino-terminal histidines, as well as delete the original 
Nco! site at the start of the core gene. This was achieved 
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Fiqure 9: Construction of Core-Histidine FUsions. 
Primer sequences and templates used for the construction of 
plasmids harboring the HCV core gene with amino and carboxyl­
terminal histidine tags. 
pQE60-HCVC 
Template: pUClSN-HCVC 
Fwd: 5' G GCC ATG GGC ACG AAT CCT AAA CCT 3' 
Rev: 5' CGG AGA TCT ACA AGA GAG CAG GGC CAG 3' 
pQE30-HCVC 
Template: pUClSN-HCVC 
Fwd: 5' GC AGA TCT ACG AAT CCT AAA CCT CAA 3' 
Rev: Standard Ml3/pUC sequencing primer (-47) 
pET3d-HCVC(C-His) 
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No PCR necessary. HCVC gene (Ncoi/Hindiii) from pQE60-
HCVC cloned directly into pET3d. 
pET3d-HCVC(N-His) 
Template: pUClSN-HCVC 
Fwd: 5' G GCC ATG GGC CAT CAC CAT CAC CAT CAC GGC ACG 
AAT CCT AAA CCT 3' 
Rev: Standard Ml3/pUC sequencing primer (-47) 
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using the primer shown in figure 9. The initiation codon 
(ATG) at the 5' end of the gene was also deleted. This was 
done to prevent it serving as a site of initiation, in which 
case it would have initiated translation of a truncated 
protein lacking the six histidine residues. The M13 reverse 
sequencing primer was used as the reverse primer, and the 
template was pUC18N-C184. The PCR product was digested with 
the enzymes Ncoi/Hindiii and ligated into pET3d which had been 
prepared by digesting it with the same pair of enzymes. 
Expression of Histidine-Tagged Core Proteins 
pQE60-HCVC and pQE30-HCVC were transformed into E.coli, 
strain M15; while the pET constructs, pET3d-HCVC(C-his) and 
pET3d-HCVC(N-his), were used to transform E.coli strain 
HMS17 4 (DE3) . Single colonies were used to inoculate 3ml 
cultures of M9 media, supplemented with 50�g/ml ampicillin 
(pET/HMS174(DE3)); or 3mls of LB media, supplemented with 
50ugfml ampicillin and 25�g/ml kanamycin (pQE/M15). The 
cultures were grown at 37°C overnight, and then used to 
inoculate 50mls of the same media. The 50ml cultures were 
grown at the same temperature until their optical density 
(600nm) measured 0.6-8.0. The cells were induced by the 
addition of lmM IPTG and grown for a further 3 hours. To test 
for expression of the histidine tagged HCV core fusion 
protein, lml of cell culture was pelleted and the cells 
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suspended in 1001-£1 of SDS-PAGE sample buffer, boiled, and 
analyzed by both SDS-PAGE and immunoblotting using a 
monoclonal anti-HCV core antibody. 
Purification of Histidine-Tagged Core Proteins 
The most efficient expresser of HCV core protein bearing 
a poly-histidine tag (pET3d-HCVC{C-his) was grown and induced 
in the manner described previously. This protein accumulated 
as insoluble aggregates following high-level expression, 
therefore it was necessary to develop a denaturing 
purification scheme in order to purify this protein. Two 
different schemes, utilizing either 8M urea, or 6M guanidine­
HCL, were used in an attempt to purify the HCV core protein 
bearing a carboxyl-terminal histidine tag. 
The cell pellet from one liter of cell culture was 
resuspended in 100ml of 100mM Na-phosphate, 10mM tris-cl, pH 
8.0, supplemented with either 6M GuHCl (A) or 8M urea (B). 
Cells were lysed by a single passage through a French pressure 
cell. The lysate was spun at 16, oooxg for 20 minutes to 
pellet insoluble material. Soluble protein was mixed with 
10ml of a 50% slurry of Ni-NTA resin (Qiagen), and stirred 
gently for 1 hour. Unbound protein was washed from the column 
by washing with buffer B, supplemented with 10mM imidazole. 
The histidine-tagged core protein was then eluted from the 
column with buffer B, supplemented with 100mM EDTA. 
50 
Generation of Polyclonal Antisera to Core Protein 
Briefly, 100�1 of core(C-his) protein (1mgfml) was 
diluted to 500�1 with PBS and mixed 1:1 with Freund's complete 
adjuvent. Following brief sonication, the homogenous emulsion 
was administered to a single New Zealand white rabbit by 
making multiple injection, subcutaneously, on the back of the 
rabbit. One month later the rabbit was 'boosted' by injecting 
antigen in a similar manner, except that the antigen was mixed 
1:1 with Freund's incomplete adjuvent. The 'boost' was 
repeated one month later. Ten days later the serum was tested 
for the presence of anti-core antibodies using immunoblots and 
the rabbit sacrificed. 
RESULTS 
Chemical Synthesis of the HCV Core Gene 
The HCV core gene was successfully synthesized, in an 
entirely chemical manner, using overlapping oligonucleotides. 
Gene fragments 2, 3 and 5 were successfully cloned by simply 
annealing, filling-in, digesting and ligating the fragments 
with pUC18N. However, attempts to clone fragments 1 and 4 by 
this method failed. This was possibly due to the fact that 
these fragments incorporated longer synthetic oligonucleotides 
causing them to have more secondary structure, andjor a higher 
proportion of truncated species. To overcome this problem 
short oligonucleotide primers (20-mers) , which were 
complimentary to the 3' end of the 'filled-in fragment', were 
used to amplify the dsDNA prior to cloning. This approach 
proved successful for the cloning of the remaining core 
fragments (1 and 4). 
The sequence of the synthesized gene, assembled in 
pUC18N, was confirmed by automated DNA sequencing (data not 
shown). 
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Expression and Purification of HCV Core Protein 
The HCV core gene was excised from pUC18N-Cl84 as an 
Ncoi/Hindiii fragment, and cloned into the pET3d expression 
vector at the same restriction sites. Upon growth and 
induction of this clone with IPTG core protein was 
successfully expressed as a 22kDa protein, with a second 
major species of 18kDa, as determined by reducing 80S­
PAGE analysis and immunoblotting (Figure 10). The presence of 
multiple species is presumably due to premature translation 
termination, andjor proteolysis. If the latter is the case, 
we predict that since cells which are boiled directly in sos­
PAGE sample buffer prior to immunoblotting, the proteolysis is 
due to an intracellular protease. Further, the fact that the 
cleaved forms of core still blot with the core monoclonal 
antibody, which is directed to the amino-terminus of the 
protein, suggests that it is the carboxyl-terminus which is 
susceptible to proteolysis. 
HCV core protein proved extremely difficult to purify, 
probably in part due to the heterogenic nature of the 
expressed protein. Despite being expressed at relatively high 
levels (5-10mg/L), only 100-500 micrograms of protein was 
typically purified per liter of cell culture. 
When analyzed by reducing SDS-PAGE, the purified protein 
ran as two species with molecular weights of 22 and 16kDa 
(Figure 11). However, in the absence of reducing agent the 
protein migrated as a macromolecular structure which failed to 
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Fiqure 10: Expression of 22kDa BCV Core Protein Following the 
Induction of Plasmid pET3d-BCVC with IPTG. SDS-PAGE (A) and 
immunoblottinq (B) with a HCV core specific monoclonal 
antibody (410G5H4) (Lanes Al & Bl - uninduced; lanes A2 & B2 -
induced). 
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Fiqure 11: SDS-PAGE Analysis of Purified HCV Core Protein 
Under Reducinq (R) and Non-Reducinq (NR) conditions. Reduced 
protein migrates as a doublet of 22 and 16 kDa, and unreduced 
protein accumulate at the top of the resolving gel. 
enter the resolving portion of the gel (Figure 11). 
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These 
observations suggest that, under native conditions, HCV core 
protein is assembled into a multimeric, disulfide-linked 
macromolecular structure. 
Physical Characterization 
Ultra-Violet Spectroscopy 
When analyzed by ultra-violet spectroscopy, HCV core 
protein did not exhibit a profile characteristic of a typical 
protein (Figure 12). Instead of a maximum at 280nm, core 
exhibited a maximum at approximately 260nm. This could be 
indicative of an association of the protein with nucleic acid. 
Gel Filtration 
Upon analysis by gel filtration chromatography, core 
protein eluted at a position consistent with it being 
assembled into a multimeric structure of high molecular weight 
(Figure 13). Recombinant HBV core protein is known to have a 
molecular weight in excess of 103 kDa (Stahl et al., 1982), 
and this experiment shows that recombinant HCV core protein 
has a molecular size in this range. The broad peak exhibited 
by HCV core protein is indicative of heterogeneity in the 
molecular size of the purified protein. 
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Figure 12: Ultra-Violet Spectrum of Core Protein. 
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Panel A, recombinant HBV core protein; Panel B, recombinant 
HCV core protein. 
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Figure 14: Electron Micrograph of Purified core Protein. 
The protein was negatively staining with tungstic acid. 
A heterogenous mixture of nucleocapsid-like particles with 
diameters ranging from 12-20nm are visible. 
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Electron Microscopy 
Examination of purified HCV core protein by electron 
microscopy revealed a heterogeneous mixture of nucleocapsid 
particles with diameters in the range of 12-20nm (Figure 14). 
Immunological Characterization of Core 
Recognition of Core Protein by TWo Monoclonal Antibodies 
Immunoblotting confirmed that the two monoclonal anti­
core antibodies were able to specifically bind core protein 
expressed in E.coli (data not shown). In order to determine 
whether or not the antibodies could bind native core protein, 
an ELISA was developed and the ability of core 
protein to capture the monoclonal antibodies was tested. The 
results, shown in figure 15, highlight the fact that both 
monoclonal antibodies have a relatively high affinity for 
native core protein, purified from E.coli. Even at antibody 
dilutions of 105, antigen-antibody associations can still be 
detected. 
These observations suggest that the amino acid sequence 
to which the monoclonal antibodies were directed is 
accessible at the surface of the protein. Further, it 
demonstrates that core protein was successfully coated to the 
wells of the microtitre plates under the 'coating conditions' 
described under 'materials and methods'. 
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Figure 15: Recoqnition of Native core Protein by Two 
Monoclonal Anti-core Antibo�ies. 
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ELISA For Detecting Anti-HCV Core Antibodies in Patients' Sera 
A series of well characterized HCV positive serum samples 
were examined for the presence of anti-core antibodies using 
the newly developed ELISA. Samples were tested at dilutions of 
1:200 and 1:1000. The results, shown in table 1, confirm that 
anti-core antibodies were detected in all 6 sera tested, at 
both dilutions. 
Histidine-Tagged HCV Core Protein 
Cloning and Expression 
In an attempt to purify milligram quantities of HCV core 
protein in a reproducible and rapid manner, a new expression 
vector was constructed. Polyhistidine-core fusions, with the 
polyhistidine residues localized at the carboxyl or amino­
terminus, were created using a commercially available kit 
(QiaExpress, Qiagen Inc.). It was envisaged that expression of 
the protein using this system would; i) afford a rapid and 
simple purification of the protein using NTA-resin (Qiagen); 
and ii) allow the purification of only full length core 
protein by virtue of the fact that truncated core protein 
would have lost the polyhistidine tag, and therefore not stick 
to the NTA resin . 
. Polyhistidine-core expression vectors, constructed using 
the commercially available pQE expression system, proved to be 
extremely poor for expressing poly-histidine tagged core 
protein. Both amino (pQE30-HCVC) and carboxyl-terminal 
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Table 1: Detection of Anti-Core Antibodies in BCV Infected 
sera. 
All samples, except NHS (normal human serum) were previously 
shown to be positive for HCV infection by a variety of 
commercial tests. 
SAMPLE ID HCV CORE REACTIVITY 
1:200 1:1000 
NHS 0.12 0.00 
4523 2.00+ 2.00+ 
4384 2.00+ 2.00+ 
12-080 8906 2.00+ 1. 25 
GJ61329 2.00+ 2.00+ 
GC 2230792 2.00+ 2.00+ 
GC2230800 2.00+ 1. 62 
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histidine fused constructs (pQE60-HCVC) exhibited levels of 
protein expression which were barely detectable by immunoblot 
analysis (Figure 16, lanes 2 & 3). 
In an attempt to increase expression levels the histidine 
tagged core genes were transferred to the pET-3d expression 
plasmid, a system which had previously been shown to 
successfully express native core protein at relatively high 
levels (Figure 10). In pET3d-HCVC(N-his) the original 
initiator methionine residue for core was deleted in order to 
prevent initiation from this point, which would result in core 
protein lacking the amino-terminal polyhistidine fusion. This 
was achieved by synthesizing a mis-match primer which inserted 
an Nco! site 5' of the six histidine codons, and deleted the 
original Nco! site. Using these vectors, both the amino­
terminal and carboxyl-terminal histidine tagged proteins were 
expressed at levels of between 5 and 10mg/L. Core protein 
bearing an amino-terminal tag, like the original untagged 
protein, was proteolyzed at it's carboxyl-terminus (Figure 16, 
lane 6). The protein was soluble, however it did not readily 
bind to the NTA-resin under native conditions. This 
observation, and the fact that this protein did bind to the 
resin under denaturing conditions (data not shown), is 
suggestive that the amino terminus of the protein is not 
exposed under native conditions. 
Surprisingly, core protein bearing a carboxyl-terminal 
histidine tag, unlike its un-tagged counterpart and the amino-
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terminal tagged protein, was insoluble and accumulated as 
inclusion bodies following expression. This presumably 
accounts for the observation that, unlike the native protein, 
this core-histidine fusion was not cleaved during expression 
(Figure 16, lane 5). This observation further supports the 
premise that the truncations observed with pET3d-HCVC are due 
to proteolysis by an intracellular protease, and not by 
premature translation termination. Presumably the expressed 
protein is not accessible to intracellular proteases when it 
is insoluble in the cytoplasm. 
Purification of Core (C-His) Using Affinity Chromatography 
Since both amino and carboxyl-histidine-tagged core 
proteins required denaturing conditions to expose the 
histidine tag, it was decided that the protein tagged at the 
carboxyl-terminus would be the best to pursue. This protein 
was expressed as a single species (Figure 16, lane 5; Figure 
17) , unlike the amino-terminal tagged protein, which was 
proteolyzed (Figure 16, lane 6). A denaturing purification 
scheme was developed to accomodate the fact that the carboxyl­
terminus tagged protein was expressed in an insoluble form. 
While 8M urea was successful in solubilizing the protein, it 
failed to stick to the nickel column in this buffer (data not 
shown). Urea is considered a 'weak' protein denaturant, and 
this is presumably why the histidine tag is insufficiently 
exposed to interact with the nickel column under these 
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Figure 16 : Immuno�lot to show the Expression of Histidine­
Tagged core Protein Using pET and pQE Expression Plasmids. 
Lane 1, M15(pRep4/pQE30) uninduced; Lane 2, M15(pRep4/pQE30) 
induced; Lane 3, M15(pRep4/pQE60) induced; Lane 4, HMS174(DE3) 
(pET3d-HCVC(C-His)) uninduced; Lane 5, HMS174(DE3) (pET3d­
HCVC(N-His)) induced; Lane 6, HMS174(DE3) (pET3d-HCVC(C-His)) 
induced. 
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conditions. However, when the cells were lysed in a buffer 
containing 6M guanidine hydrochloride, a 'strong' protein 
denaturant, the protein stuck to the nickel column. Despite 
extensive washing of the column, and the use of an 
imidazole gradient to elute the protein, a small amount 
of contaminating proteins co-eluted with the core protein 
(Figure 18). The protein was determined to be approximately 
90% pure according to SDS-PAGE. 
Polyclonal Anti-Core(C-his) Antisera 
Anti-sera raised against purified core {C-his) specifically 
recognized both histidine tagged and native HCV core protein 
when tested using immunoblots (Figure 19). 
core--> 
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Figure 17: SDS-PAGE to Show the Expression of HCV core (C­
his). 
Lane 1, 1 hr induction; lane 2, 2 hour induction; lane 3, 4 
hour induction; lane 4, pre-induction. 
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40.0-
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14.4-
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<- Core (C-His) 
Figure 18 : SDS-PAGE of Core (C-His) Purified �y Affinity 
Chromatoqraphy. 
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1 2 3 4 
Figure 19 : Immunoblot to show the Recognition of Core(C-His) 
and Native Core By Polyclonal Anti-core(C-His) Antisera. 
Lanes 1 & 2, pET3d-HCVC(C-His) in HMS174(DE3); lanes 3 & 4, 
pETHCVC in HMS174(DE3). Whole E.coli cell lysates , either 
preinduced (lanes 1 & 3), or following induction with IPTG 
(lanes 2 & 4), were used. 
DISCUSSION 
The hepatitis C virus has recently emerged as a health 
concern of worldwide significance. In the past 5 years over 
90% of the cases of non-A, non-B hepatitis have been shown to 
be attributable to this virus. The majority of individuals 
who become infected with this virus develop chronic 
infections, which have been shown to be associated with the 
development of primary liver cancer (Colombo et al., 1989; 
Saito et al., 1990; Nishioka et al., 1991; Ohkoshi et al., 
1990}. 
At the present time there is not a vaccine which 
specifically targets the hepatitis c virus, although trials 
are underway (Chao et al., 1994}. Therefore, there is a 
great need for rapidly and reliably diagnosing HCV infected 
individuals, both to reduce transmission of the virus, and 
to enable infected individuals to begin therapy. Treatment 
with alpha-interferon, particularly when administered during 
the acute stage of infection, has been shown to be successful 
in treating some patients (Davis et al., 1989; DiBisceglie et 
al., 1989). 
The capsid, or core protein, which is encoded by the 
amino-terminal region of the viral polyprotein, has emerged as 
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one of the most immunogenic proteins encoded by the virus (Hsu 
et al., 1993; Harada et al., 1991; Chiba et al., 1991). 
Accordingly, core fusion proteins are an important component 
of diagnostic ELISA's and RIBA's. The focus of this study 
was to develop an expression system for generating milligram 
quantities of full-length core protein. It was envisaged that 
this would permit the structural, functional and immunological 
characteristics of this protein to be investigated, as well as 
providing an antigen for capturing antibodies in a diagnostic 
ELISA. 
The hepatitis C virus core gene was chemically 
synthesized using overlapping oligonucleotides (Rossi et al., 
1982; Scapulla et al., 1982), and the synthetic gene was 
successfully expressed using a T7 polymerase based expression 
system. During the course of this study a new method for the 
chemical synthesis of genes was reported (Khudyakov et al., 
1993). Coincidentally, the first gene synthesized using this 
procedure, the 'Exchangeable Template Reaction', was also the 
hepatitis c core gene. In this reaction, pairs of 
oligonucleotides are annealed, filled-in with polymerase, and 
then digested at their 3' terminus with a restriction enzyme 
that creates a 3' overhang. This overhang allows the annealing 
of the next oligonucleotide. Following a second filling-in 
step, the product is digested again to allow the annealing of 
the next primer. In the original report the restriction 
enzyme 'BstX1' was used at each step. The product of this 
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digestion is a 4bp overhang, which was apparently sufficient 
to permit the annealing of the next primer. One clear 
shortfall in this procedure is it's inability to facilitate 
the exchange of regions of the gene for future studies. This 
may have important implications in the study of different core 
subtypes, which will merely require the replacement of one of 
the gene fragments using our construct. 
Despite being expressed in a soluble form at levels of 5-
10mg/L, HCV core protein proved extremely difficult to 
purify. This may be in part due to the apparent heterogeneity 
of the protein which is evident in immunoblots of total cell 
lysates (Figure 10). Despite the fact that core proved 
difficult to purify, the protein was successfully purified in 
sufficient quantities to begin structural and immunological 
characterization of it. 
Probably the most interesting finding of this study is 
that hepatitis C core protein appears to assemble into a 
multimeric, disulfide-linked, particulate structure. To our 
knowledge, this is the first time that spontaneous assembly of 
hepatitis c core protein has been reported using protein 
acquired from a recombinant source. The particles appear 
somewhat heterogeneous when examined by both gel filtration 
chromatography (Figure 13), and electron microscopy (Figure 
14), exhibiting an apparent diameter of 12-20nm. Accordingly, 
it is difficult to ascertain whether the core protein is 
truely assembled into core particles, or is subject to non-
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specific aggregation. 
A single report published in 1992 described the isolation 
and visualization of 33-nm nucleocapsid structures, associated 
with viral-like particles with a diameter of 55-nm, from 
hepatitis c infected serum (Takahashi et al., 1992). This is 
somewhat larger than earlier reports of viral-like particles 
of 39-46nm derived from tissue culture (Jacob et al., 1990). 
Further, the core protein associated with the 33-nm 
nucleocapsid particles isolated from serum was estimated by 
SDS-PAGE to have a molecular size of 26kDa. This is 
significantly larger than the 22kD species observed after 
expression of the viral genome in a variety of Eukaryotic 
expression systems, including baculovirus (Hsu et al., 1993), 
monkey cos cells (Harada et al., 1991) and in vitro 
translation (Hijikata et al., 1991). The reason for this 
apparent discrepancy has yet to be resolved. 
One possible explanation for the apparent instability and 
heterogeneity of core protein expressed in E.coli could be 
that the carboxyl-terminus of core has not been accurately 
determined in vivo. It has previously been reported that core 
arises after cleavage of the core-E1-E2 precursor by a host 
signal peptidase in the endoplasmic reticulum, and that the 
amino-terminus of E1 starts at amino acid 192, and E2 starts 
at 384. Interestingly, both of these 'cleavage sites' are 
preceded by two hydrophobic sequences (174-191 and 371-383), 
that may act as signal sequences to direct the insertion of 
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the viral glycoproteins into the membrane of the ER (Hijikata 
et a1., 1991). 
A recent report by Santolini and coworkers (Santolini et 
al., 1994) suggests that the hydrophobic region at the 
carboxyl-terminus of core (H1) , and predicted to be the 
membrane insertion sequence of E1 (Hijikata et al., 1991), may 
in fact represent the membrane insertion sequence of core 
(Figure 20). It was demonstrated using an in vitro 
translation system that H1 was cleaved from core, but only in 
the presence of microsomal membranes and the signal 
recognition particle. This would suggest that mature core 
protein is 173 and not 191 amino acids long. Further, this 173 
amino acid protein, which was processed in vitro, was shown 
to co-migrate with core protein expressed in cell culture when 
examined by SDS-PAGE (Santolini et al., 1994). 
If this is indeed the case, and mature core protein is 
shorter than initially anticipated, then it raises many 
interesting points regarding the expression of core protein in 
E.coli. It is possible that the presence of the hydrophobic 
signal sequence may destabilize core protein, and/or render it 
more susceptible to intracellular proteases. Further, it may 
function to prevent correct folding of the protein, or 
particle assembly, until the protein has been successfully 
exported to the endoplasmic reticulum and the signal sequence 
removed. Alternatively, the protein may fold correctly but 
the putative signal sequence may be exposed at the surface of 
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Pigure 20: Schematic Representation of the Signal Sequence 
(Hl) Involved in the Intracellular Tarqetinq of core and Bl. 
Adapted from Santolini et al., 1994. 
Hl 
161 173 174 191 
I I 
I I 
GVNYATGNLPGCS 
I I 
I I 
FSIFLLALLSCLTTPASA 
....__ c_o_R_E __ '-11 �� ---E-2-/-NS -l----, 
1 192 384 861 
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the protein, and therefore be readily accessible to 
intracellular proteases. This would be in accordance with our 
observation that the carboxyl-terminus of core is susceptible 
to proteolysis during expression in E.coli. 
Whatever the effect of the carboxyl-terminal signal 
sequence on the stability and folding of core it will be 
simple to modify our existing E.coli expression plasmid such 
that it directs the expression of core protein of 173 amino 
acids. Truncation of our clone, such that it directs the 
expression of a 173 amino acid species, will result in the 
removal of 11 amino acids from the carboxyl-terminus 
(FSIFLLALLSC). This sequence is clearly very hydrophobic in 
nature, and it will be interesting to ascertain if this clone 
synthesizes a more stable, homogeneous, and therefore more 
easily purifyable form of the hepatitis c core protein. 
It has recently been reported that different HCV isolates 
have the potential to direct the expression of different forms 
of core protein (Lo et al., 1994). A lysine residue at 
position 9 (HCV-1) leads to the synthesis of p16, while an 
arginine at this position (HCV-RH) leads to the synthesis of 
p21. It remains unclear as to how this conservative 
substitution exerts such a dramatic effect on the size of the 
processed protein. However, this observation does highlight 
the fact that mechanisms governing the synthesis of core 
protein may be more complicated than originally thought. The 
variant constructed in this study has an arginine at position 
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9, so therefore would be predicted to be 22kDa in size. It 
will be interesting to determine if the substitution of this 
amino acid to lysine affects core particle formation. our 
E.coli expression system should allow investigation of this. 
The ultra-violet spectroscopy profile of core suggests 
that HCV core protein is able to bind nucleic acid (Figure 
12). It is likely that the nucleic acid binds to the basic 
regions of the protein, effectively neutralizing its extreme 
basicity (pi=11.94). This may also help to explain why core 
protein appears to behave as if it has a much more acidic 
isoelectric point than predicted by it's amino acid sequence, 
adhering to an anion exchange column at neutral pH (data not 
shown) . It is widely accepted that the affinity between core 
protein and nucleic acid is involved in the formation of the 
nucleoprotein complex during assembly of the virus. 
In addition to it's involvement in nucleoprotein complex 
formation, a recent report has implicated HCV core protein in 
regulating gene expression. Specifically, it has been shown 
that the amino-terminus of core (1-122), which is also the 
most basic, binds to HBV RNA and inhibits the assembly of HBV 
core particles (Shih et al., 1993). The significance of this 
observation is still unresolved, but it has been speculated 
that HCV core protein may play a regulatory role in the gene 
expression of infected cells (Santolini et a1.,1994). It will 
require more experimental evidence before this proposal gains 
wide acceptance. 
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The association of viral core proteins with nucleic acid 
following expression in E. coli has been observed in our 
laboratory, as well as several others, with the hepatitis B 
virus core protein. The carboxyl-terminus of this protein 
contains 16 arginine residues out of a total of 30 amino acids 
(53% arginine) • When expressed in E. coli, core protein 
lacking this 'arginine-rich tail' loses its ability to bind 
nucleic acid, suggesting that the nucleic acid binds 
exclusively to this region of the protein. In hepatitis C 
core protein the basic amino acids are not clustered toward 
the carboxyl-terminus in the manner that they are in hepatitis 
B core protein, instead they are scattered throughout the 
protein. Overall the protein contains 16.8% basic residues and 
they are generally clustered toward the amino terminal two­
thirds of the protein. Within this region, 22 (18.2%) of the 
residues are arginine, and 7 (5.8%) are lysine, meaning that 
in combination 24% (29/121) of the amino acids in this region 
are basic. The yellow fever virus, which is the prototype 
member of the Flaviviridae, also has an extremely basic core 
protein. In this protein 27% of the amino acids are lysine or 
arginine, highlighting the conserved nature of this basicity 
in viral core proteins. 
Previous reports have shown that the detection of 
antibodies directed at the hepatitis C core protein are an 
important marker for detecting HCV infection (Puoti et al., 
1992; Van der Poel et al., 1991). In addition to appearing 
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early in infection, the conserved nature of the protein means 
that subtype variability between different viral isolates is 
not a major concern when addressing core proteins. Only two 
major core subtypes have been described to date (Figure 2). 
In this study we expressed core protein from subtype 1; 
however, the construction of the other core gene, subtype 2, 
will be simple to achieve using our chemically synthesized 
gene. The region of variability between the two core subtypes 
is located on fragment 2 of our chemically synthesized gene. 
Simple replacement of this fragment with a fragment bearing 
the amino acid changes that specify subtype 2 will be simple 
to achieve (Figure 4). A detailed comparison of the 
properties of the two core subtypes will assist in the 
determination of the role, if any, of this subtypic 
variability in the core protein. 
Two anti-core monoclonal antibodies were shown to have a 
high affinity for native core protein expressed in E. coli 
(Figure 15). This indicates that the amino acid sequences to 
which the antibodies were raised, are exposed at the surface 
of core protein. Further, the fact that the monoclonal 
antibodies were raised against synthetic peptides suggests 
that the epitopes that they recognize are not 
conformationally-dependent. These findings highlight a 
possible use for these antibodies in immunohistochemistry. 
studies are currently underway, in collaboration with the 
Department of Pathology at the 'Medical College of Virginia', 
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to study the cellular distribution of core protein in liver 
tissue from patients infected with the hepatitis C virus. 
It has previously been shown that a strong T-cell 
response to core protein is correlated with a benign course of 
HCV infection (Botarelli et al., 1993). While 73% of healthy 
seropositive individuals responded to core protein, only 11.5% 
of patients with chronic infections were responsive at the T­
cell level. This indicates that the patients who develop 
chronic infections are those whose immune systems fail to 
mount an adequate T-cell response to core protein. Despite 
the recent identification of two HLA class-1 restricted 
epitopes on HCV core protein (Kozeil et al., 1993), it remains 
to be determined whether these sites are directly involved in 
the differentiation between acute and chronic infections. The 
fact that class-1 restricted epitopes are the target of 
cytotoxic T-lymphocytes, which destroy virally infected cells, 
means that it is likely that these sites play a role in viral 
clearance during acute hepatitis C infection. 
T-cell responses are mediated by the presentation of 
fragments of antigen in association with 'self' MHC molecules. 
The fact that antigen is presented in the form of linear 
peptide fragments means that linear, or denatured protein, is 
perfectly suitable for carrying out such studies. For this 
reason, we believe the purified histidine-tagged core protein, 
which can be reproducibly purified in milligram quantities, 
will be a useful tool for investigating T-cell responses to 
the full-length core protein. 
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These studies are currently 
underway in collaboration with Dr. David Milich at 'Scripps 
Research Institute.' Previous studies of the T-cell sites on 
core have been conducted using SOD-core fusions which only 
include the amino terminal region of core (Botarelli et al., 
1993). Therefore, it is probable that other undefined T-cell 
sites are present at the carboxyl-terminus of the protein. 
Characterization of this interaction between the host immune 
system and HCV core protein at the T-cell level will have an 
important role in the development of immunomodulatory agents 
and in vaccine development. 
In contrast to T-cell responses, 
observed in almost all chronically 
B-cell response are 
infected individuals 
(Harada et al., 1991; Chiba et al., 1991; Hosein et al., 1991; 
Muraiso et al., Nasoff et al., 1991). Since a little over 10% 
of chronically infected patients develop T-cell responses, 
antibody responses to core must be occurring in an apparent 
absence of a detectable Tb-cell response. This mechanism of 
'T-cell help' has previously been reported in hepatitis B 
virus infection and involves a process termed 'intermolecular 
help' (Milich et al., 1987). In short, T-cell responses to 
other viral proteins are able to provide the necessary T-cell 
help to B-cells and enable them to be stimulated to secrete 
antibody. It is possible that a similar mechanism occurs in 
HCV to allow universal B-cell responses in the apparent 
absence of T-cell help. 
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The most important epitopes for detecting hepatitis c 
infection at the present time are localized within the core 
and NS3 proteins. Accordingly, a European group has recently 
reported the characterization of core-NS3 fusion protein 
expressed and purified from E.coli (Osbourne et al., 1993). 
The chimera contains the amino-terminal 105 amino acids of 
core, the region which is widely accepted as being the most 
immunogenic, fused to residues 1186-1364 of NS3. The protein 
has been shown to be effective in differentiating between 
hepatitis C infected individuals and healthy donors. However, 
while this approach is useful for detecting infected serum 
samples, it has a limited value in studying the individual 
serology of patients. 
Recent observations by Feinstone and co-workers suggest 
that B-cell epitopes are not limited to the amino-terminal 
region of core. This highlights the necessity for 
incorporating full-length core protein for capturing anti­
core antibodies in diagnostic assays. The newly described B­
cell sites are located at amino acids 133-142 and 165-174 
(Akatsuka et al., 1993); sequences which are not included in 
recently developed antigens designed for capturing anti-core 
antibody (Osbourne et al., 1993; Chen et al., 1992). 
Likewise, the appreciation that core protein probably harbors 
B-cell sites which are conformationally dependent also 
suggests that full length, native core protein will have many 
benefits over core fusions and synthetic peptides for 
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diagnosing HCV infection. It has recently been shown that in 
patients infected with HIV, over 50% of the B-cell epitopes 
on p24, the HIV core protein, are conformationally dependent 
determinants (Haist et al., 1993). This signifies the 
importance of an ability to mimic the structure of the native 
viral antigens when developing diagnostic assays, and also 
when studying the interaction between viral proteins and the 
immune system of the host. In this regard, our soluble E.coli 
derived core protein will serve as a useful tool for studying 
conformational epitopes. 
The mapping of B-cell determinants on core provides 
support for the model of Santolini and coworkers ( 1994) 
regarding the carboxyl-terminal processing of core. So far 
no B-cell sites have been mapped to the amino acids 174-191, 
the region of core which is proposed to be cleaved during core 
protein maturation. This is despite the fact that the terminal 
regions of proteins are often surface exposed, suggesting that 
this sequence may indeed be cleaved off prior to nucleocapsid 
assembly. The recent identification of an epi tope within 
amino acids 165-174 (Akatsuka et al., 1993) suggests that 
amino acid 173 could indeed represent the carboxyl-terminus 
of the mature protein. However, it should also be noted that 
the amino acids encompassing 174-191 are generally hydrophobic 
in nature. Therefore, it is conceivable that this sequence may 
be present on mature core protein, but due to it's low 
immunogenicity is not the target of an antibody response. 
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Our preliminary ELISA results suggest that core protein 
expressed and purified from E.coli will be an excellent source 
of recombinant protein for a number of different applications. 
The ability of core protein to bind antibodies from HCV 
infected sera make it particularly useful for use in a 
diagnostic assay. We are currently working on improving the 
purification scheme for this protein so that we can purify 
large quantities of protein (>lOOmg). Having larger amounts 
of protein at our disposal will also facilitate the 
continuation of structural and immunological studies. 
This task of purifying larger quantities of core protein 
is being approached in two different ways. The first 
approach involves the expression of core as a carboxyl­
terminal histidine tagged fusion. This protein can be purified 
rapidly, and in a reproducible manner using nickel chelation 
chromatography. We have successfully expressed and purified 
this protein, under denaturing conditions, and are now in the 
process of developing a procedure for successfully refolding 
this protein such that it is soluble in the absence of 
denaturing agents. Osbourne and coworkers have successfully 
refolded an NSJ-core fusion protein, for use as a diagnostic 
agent, using the method of Cleland (Cleland et al., 1992). 
Accordingly, it is reasonable to assume that this procedure 
will serve as a useful starting point from which to begin 
attempts to refold full-length core protein. 
The second approach for generating more core protein is 
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to remain with the original expression system (pET3d-HCVC), 
but to develop an efficient ELISA for monitoring the 
purification of the protein. It is envisaged that a rapid 
assay for the protein could limit the degree of proteolysis of 
core by E.coli proteases. The original purifications were 
achieved primarily using SDS-PAGE gels and immunoblotting, 
both of which are very time consuming procedures. We have 
generated polyclonal antisera to the histidine tagged core 
protein and shown that this antisera specifically recognizes 
both histidine-tagged, as well as untagged core protein 
(Figure 19). We are currently investigating the possibility 
of using the purified IgG to develop a sandwich ELISA for 
detecting core protein. The availability of a rapid and 
sensitive ELISA will be valuable asset for developing improved 
purification procedures for core in the future. 
The expression and purification of full-length HCV 
proteins not only allows one to study the structure/function 
aspects of individual viral proteins, and develop diagnostic 
ELISA's, but also allows the dissection of the immune response 
as it relates to individual proteins. This is already possible 
when considering hepatitis B infection, where the detection of 
specific antigens (e.g. 'e' , core, and surface antigen) as 
well. as antibodies to specific viral antigens (e.g. anti-'e', 
anti-core, and anti-surface antigen) allows a more detailed 
and therapeutically useful serology to be generated for each 
individual (Hoofnagle and Di Bisceglie, 1991). In hepatitis B 
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it is now possible to differentiate between chronic and acute 
infections by detailing the immune response of the patient to 
individual proteins. 
At the present time there is little evidence for a 
correlation between antibody production to certain proteins 
and the status of the hepatitis C infection in individual 
patients. However, a transient IgM response to core has been 
observed, and proposed as a potential marker of acute or 
active HCV infection (Chen et al., 1992). The development of 
immunoassays which specifically identify antibodies to 
individual proteins, such as core, will likely form the basis 
of future diagnostic assays. 
CONCLUSIONS 
Hepatitis C core protein, over-expressed and purified 
from E.coli, appears to be a useful tool for understanding the 
basic biochemistry of 
applications in the 
this virus, 
medical 
and also has potential 
field. Biochemically, 
recombinant core protein appears to exhibit several of the 
features that would be predicted for a viral core protein 
which is involved in nucleocapsid assembly. These include an 
affinity for nucleic acid, 
multimeric, particulate 
and spontaneous assembly into a 
structure. Accordingly, this 
recombinant protein would appear to be a useful tool for 
studying the structure and function of hepatitis c core 
protein. 
Preliminary results suggest that this antigen is 
extremely effective in capturing anti-core antibodies from HCV 
infected sera. This is likely to be in part due to the ability 
of recombinant core protein to bind conformationally dependent 
antibodies in addition to those recognizing linear 
determinants. It is expected that this observation will 
ultimately be harnessed in the development of a marketable 
diagnostic ELISA. The detection of anti-core antibodies will 
have important implications, not only for reliably detecting 
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HCV infections, but also for studying the immune 
responsiveness of patients to core protein. Current HCV 
ELISA's incorporate epi topes from several different viral 
proteins, and are therefore unable to provide information 
regarding antibody responses to individual proteins. An 
ability to more precisely categorize the immune status of 
individual patients may help to uncover as yet hidden 
information regarding the different clinical courses of HCV 
infection. 
IT. CLONING, EXPRESSION, PURIFICATION AND 
CHARACTERIZATION OF TilE MAJOR CORE PROTEIN (P26) 
FROM EQUINE INFECTIOUS ANAEMIA VIRUS 
INTRODUCTION 
THE LENTIVIRIDAE 
The Lentiviridae are a family of animal viruses which are 
a subfamily of the Retroviridae (Charman et al., 1976; Penny 
1988; Stephens et al., 1986). The most intensively studied 
member of this family of viruses has been the human 
immunodeficiency virus (HIV), which was classified as a 
lentivirus in the mid-1980's (Chiu et al., 1985). Other 
members of this family of viruses are the equine infectious 
anaemia virus (EIAV/horses), caprine arthritis-encephalitis 
virus (CAEV/goat), bovine immunodeficiency virus (BIVfcow), 
feline immunodeficiency virus (FIVfcat), visna virus (sheep), 
and simian immunodeficiency virus (SIV/primate). These non­
oncogenic, chronic disease causing lenti viruses have identical 
morphology, and are characterized by genetic andjor antigenic 
variation during persistent infection (Hahn et al., 1986; 
Issel et al., 1986; Montelaro et al., 1986; Salinovich et 
al., 1986; Hussain et al., 1987; Payne et al., 1987). The 
biologic and genetic relationship between the non-human 
lentiviruses and HIV-1 renders them potentially useful models 
for understanding the pathogenesis of HIV-1, and for 
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evaluating methods of effective treatment and control of viral 
infection (Letvin, 1990). 
Equine infectious anaemia virus (EIAV), which was one of 
the first viruses identified in nature in 1904, is 
responsible for causing a chronic, debilitating disease in 
horses (Issel and Coggins, 1979). EIAV infection has been 
reported worldwide and is recognized as a livestock pathogen 
of significant economic importance to the horse industry. The 
early stages of infection are characterized by repeated, acute 
episodes of fever, weight loss and anaemia, with intervening 
periods of clinical quiescence. The progression to a chronic 
infection is typically manifested by arthritis, encephalitis, 
progressive pneumonia and slow neurological diseases (Issel 
and Coggins, 1979). 
Genomic Organization of Lentiviruses 
Members of the Lentiviridae share many common features, 
including a large RNA genome of 9 kb or more in length, and 
exhibit conserved genomic organization (Table 2) • Like 
other complex retroviruses, lenti viruses exhibit a more 
complex genome than the other class of retroviruses - the so­
called 'simple retroviruses'. Simple retroviruses, such as 
feline leukaemia virus (FeLV) and Reus sarcoma virus (RSV), 
are entirely dependent upon host cell transcription factors to 
regulate gene expression. In contrast, the complex 
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Table 2: Characteristics of Common Lentiviruses. 
(Reproduced from, 'Pathogenesis of human 
immunodeficiency virus infection', 
by Jay A. Levy, Ph.D. 
Microbiological Reviews, March, 1993) 
Clinical 
Association with a disease with a long incubation period 
Association with immune suppression 
Involvement of hematopoietic system 
Involvement of the CNS 
Association with arthritis and autoimmunity 
Bioloqical 
Host species specific 
Exogenous and nononcogenic 
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Cytopathic effect in certain infected cells, e.g., syncytia 
(multinucleated cells) 
Infection of macrophages, usually noncytopathic 
Accumulation of unintegrated circular and linear forms of 
viral eDNA in infected cells 
Latent or persistent infection in some infected cells 
Morphology of virus particle by electron microscopy: cone 
shaped nucleoid 
Molecular 
Large genome (>9 kb) 
Truncated gag gene: several processed Gag proteins 
Highly glycosylated envelope protein 
Polymorphism, particularly in the envelope region 
Novel central open reading frame in the viral genome that 
separates the pol and env regions 
Presence of accessory/regulatory genes 
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retroviruses encode several viral transactivators which enable 
them to exert more control over the expression of their viral 
genes. The synthesis of viral specific transacti vators, 
encoded by early, regulatory mRNA's, enables complex 
retroviruses to adopt a replication cycle which can be divided 
into two different temporal phases. The 'early', or 
'regulatory genes', encode a nuclear regulatory protein 
(called Tat in HIV), which transactivates 'long terminal 
repeat' (LTR) driven gene expression. This activation results 
in an increase in the levels of a second regulatory protein 
(called Rev in HIV), whose function is to activate the 
expression of the viral structural proteins (for review, see 
Levy, 1993) . 
Although the regulatory mechanisms of EIAV have not been 
studied as intensively as they have in HIV, recent reports 
suggest that EIAV encodes a highly homologous transcription 
transactivator (Dorn et al., 1990), which appears to be 
mechanistically similar to HIV-1 Tat (Carroll et al., 1991). 
Further, other aspects of the EIAV replication cycle, such as 
the identification of a functional candidate rev gene product 
(Stephens et al., 1990) would appear to further confirm the 
evolutionary relationship between HIV-1 and the various animal 
lentiviruses. 
The two late/structural mRNA's, which are transcribed in 
response to transactivation by Rev, include a singly spliced 
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(Env) and unspliced {Gag-Pol) mRNA. The former gives rise to 
the envelope glycoproteins, gp90 and gp45 in EIAV (gp120 and 
gp41 in HIV-1). Translation of the latter mRNA (Gag-Pol) 
generates two precursor polyproteins, also called Gag and Pol. 
Ribosomal frameshifting during the translation of the 3' end 
of gag (Figure 21) accounts for the 20-fold higher relative 
abundance of the Gag precursor protein over Pol. Both 
precursors are subsequently processed by the viral protease to 
yield several functional proteins. The Pol precursor, which is 
82kDa in EIAV, is cleaved into the following products: 
reverse transcriptase (RT); protease (PR); and the integrase 
(IN), which is involved in the integration of the virus into 
the genome of the host to form a provirus. 
Lentiviral Core Proteins 
Structure and Function 
The gag (or core) open reading frame is located at the 
5' end of the genome, immediately following the 5' long -
terminal repeat {LTR) (Figure 21), and is the first gene to be 
translated. Consistent with other lentiviruses, four different 
EIAV Gagjcore proteins have been identified; p26 (major 
structural protein), p15 (matrix protein), p11 (nucleic acid 
binding protein) and p9 (unknown function) (Henderson et al., 
1987). Previous studies have shown that all four core proteins 
are derived from the processing of a single 55kDa precursor 
(Montelaro et al., 1982; Hussain et al., 1988). The Gag 
�.__P_l_s_,__ P_2_6_�I._P_l_l....JI._P_9....JI 
Gag (pSS) 
Pol (p82) 
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Figure 21: Schematic Representation of the Gag and Pol Regions 
of the Lentiviral Genome. LTR, long-terminal repeat. The 
molecular weights of the precursor proteins are shown in 
parenthesis, and the sizes of the four individual Gag proteins 
refer to the equine infectious anemia virus. 
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precursor polyprotein appears to be cleaved by a 10kDa 
protease, which is derived from the Pol precursor, to generate 
the four major non-glycosylated internal proteins of EIAV. 
Retroviral Gag proteins retain the ability to direct the 
formation of virion-like particles, even when expressed in 
the absence of all other virus encoded proteins (Shiota et 
al., 1990; Delchambre et al., 1989; McGuire et al., 1994; 
Wills, 1989). Further, mutations in the Gag proteins have 
been demonstrated to cause retroviruses to lose their ability 
to bud from the plasma membrane of the host cell. Hence they 
are frequently referred to as the 'particle making machinery' 
of the virus. 
A recent report concerning the processing of the 55kDa 
EIAV Gag precursor in a recombinant vaccinia virus system 
demonstrated that sub-viral core particles could be produced 
when recombinant vaccinia contained only p55. However, in the 
presence of the viral protease, the sub-viral particles, 
although morphologically indistinguishable, contained 
processed p26 protein (McGuire et al., 1994). An inability to 
detect processed p26 in the absence of the viral protease 
indicates that the major structural protein (p26) is cleaved 
from the Gag precursor by the viral protease (McGuire et al., 
1994) • The capability of subviral particles to form in the 
absence of proteolytic processing of the Gag precursor has led 
to the speculation that proteolytic cleavage of the Gag 
precursor may occur after particle assembly. This is supported 
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by similar observations which have been made for HIV-1 (Gowda 
et al., 1989; Karacostas et al., 1989). 
The matrix protein, which is 15 kDa in EIAV (17 kDa in 
HIV-1) , is located at the amino terminus of the Gag precursor 
(Figure 21) and ultimately forms an intimate association with 
the cytoplasmic face of the plasma membrane. Although this 
protein is not directly associated with other Gag proteins in 
mature virions, it is believed to play a role in directing the 
Gag precursor protein to the site of assembly on the plasma 
membrane. In HIV-1 the matrix protein has been shown to be 
essential for infectious particle formation (Bryant and 
Ratner, 1990; Gottlinger et al., 1989) 
The nucleocapsid protein of EIAV (p11), like that of all 
retroviruses, contains 'Cys-His' boxes (C-X2-C-X4-H-X4-C) which 
appear to play a crucial role in both the packaging and 
dimerization of the viral RNA genome, but not in particle 
formation (Meric et al., 1986; Meric et al., 1988; Dupraz et 
al., 1990; Gorelick et al., 1990). 
Subviral Particle Formation 
In HIV, myristoylation of the p55-Gag precursor has been 
demonstrated to be essential for virion infectivity (Bryant 
and Ratner, 1990; Gottlinger et al., 1989). The primary 
function of the myristic acid appears to be in targeting p55-
Gag to the plasma membrane. This has lead several groups to 
suggest that membrane association may involve a specific 
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receptor located on the cytoplasmic face of the plasma 
membrane, analogous to p60v-src of Reus sarcoma virus (Resh, 
1989; Wills and Craven, 1991). However, EIAV, like several 
retroviruses, is able to replicate without the need for 
myristoylation (Henderson et al., 1987), indicating that other 
recognition mechanisms probably exist. 
Recently it has been reported that in addition to the 
myristic acid moiety, a domain within the matrix (MA) region 
of HIV-1, downstream of the myristoylation site, is also 
required for a stable association between p55-Gag and the 
plasma membrane (Spearman et al., 1994). Once in contact with 
the plasma membrane, the p55-Gag protein associates with the 
envelope proteins which are transported from the endoplasmic 
reticulum via the secretory pathway. The subsequent assembly 
of virions occurs simultaneously with the budding and release 
of immature viral particles. 
During maturation the spherical, electron dense structure 
seen in immature particles condenses to form a cone-shaped, 
eccentrically located nucleoid. The translocation of p24 from 
a peripheral position to a more internal position relative to 
the viral membrane is also evident during maturation 
(Gelderbloom et al., 1987). This migration of the core 
protein (p24) has been shown to be essential for viral 
infectivity, suggesting that disruption of correct viral core 
assembly could serve as an anti-HIV therapy (Gottlinger et 
al., 1989) . 
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Comparison of HIV and EIAV Hajor Core Proteins 
The major EIAV core protein shares significant homology 
with the major core proteins of other members of the 
lentivirus family of viruses, most notably a 55% amino acid 
similarity (30% identity) with the major core antigen of HIV-1 
(Figure 22) (Stephens et al., 1986). Indeed, serum from EIAV 
infected horses has been shown to precipitate the major core 
antigens of HIV-1 (Montagnier et al., 1984), and FIV (Egberink 
et al., 1990; Steinman et al., 1990). This is indicative of 
the presence of conserved inter-species determinants among the 
lentiviral core proteins, prompting suggestion that the major 
core proteins of HIV-1, EIAV, FIV and BIV are organized into 
similar antigenic domains (Chong et al., 1991; Egberink et 
al., 1990). The major antigenic sites for these proteins 
appear to be localized within their carboxyl-termini 
(Windheuser et al., 1989). 
Structural similarities between the major core proteins 
of HIV-1 and EIAV have been suggested as a result of a 
previous study conducted using a series of p26 fusion 
proteins. It was demonstrated that a 15 amino acid region of 
p26 (153-167), 10 of which are identical to the corresponding 
region in p24 from HIV-1, defines an epitope which binds a 
particular monoclonal antibody which also bind to the core 
proteins of HIV-1, HIV-2 and SIV (Nishimura et al., 1984). 
This sequence forms part of a 20 residue sequence termed the 
major homology region (MHR) (Figure 22) (Patarca et al., 1985). 
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Figura 22: Alignment of BIAV (above) and BIV-1 (below) Cora 
Protein sequences. 
The major homology region (MHR) (amino acids 277 to 296) is 
indicated. (Gap Weight� 3.000; Average Match� 0.540; Length 
Weight= 0.100; Average Mismatch • -0.396; Quality= 151.1; 
Length = 239; Ratio z 0.654; Gaps • 4; Percent Similarity = 
54.825; Percent Identity= 29.386). 
(KEY: A bar (I) indicates identity; a colon (:) indicates 
conservation; a period (.) indicates weak conservation. 
Cysteine (*) and tryptophan (+) residues of EIAV core are 
indicated). 
+ * 
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1 PIMVDGAGNRNFRPLTPRGYTTWVNTIQTNGLLNEASQNLFGILSVDCTS 50 
1 1  • •  I 1 . 1 1  II •• •• I . 1 . 1 . 1  ., . . .  ,. . . , .. ,, .... ,, .... ... . , . . .  ,. , . . . , .  
1 PIVQNLQGQMVHQPISPRTLNAWVKVVEEKAFSPEVIP.MFSALAEGATP 49 
+ 
51 EEMNAFLDVVPGQAGQKQILLDAIDKIADDWDNRHPLPNAPLVAPPQGPI 100 
••• 1 . 1 .  I I. • 1 . 1 • 1 .  I . 1 1 1 1  • •  1 . 1 1 I 
· · · 1 · · 1 · · 1 · 1 · · · · · 1 · 1 · · I · ·  1 • • 1 1 • 11••••1 •11• 1 • 
50 QDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGP.IAPGQMRE 98 
+ 
101 PMTARF ... IRGLGVPRERQMEPAFDQFRQTYRQWIIEAMSEGIKVMIGK 147 
I • I •• • •  . 1 . 1 1 1  • • •• 1 .  ,... . . .. , . . .. . . .. .. , . .  ,,, .... .. , .. . 
99 PRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVR.MYSP 147 
MHR 
148 PKAQNIRQGAKEPYPEFVDRLLSQIKSEGHPQEISKFLTDTLTIQNANEE 197 
. 1 1 1 1 . 1 1 1  • •• Ill . •• I 1 • • •• 1 . 1 1 . 1 1 1 1  • .,,,,.,,, .... ,., . .. . .. , . .  ,...... ,.,, .,,,, .. 
148 TSILDIRQGPKEPFRDYVDRFYKTLRAEQASQDVKNWMTETLLVQNANPD 197 
* * 
198 CRNAMRHLRPEDTLEEKMYACRDIGTTKQKMMLLAKAL 235 
I • •• I I  1 1 1 1 1 1 1  •• 1 .I . I  I •• •• I 1 ••111 1 •1 1 1 •••1•• •I ••I 
198 CKTILKALGPAATLEEMMTACQGVGGPGHKARVL .... 231 
103 
This region, in addition to harboring a conserved B-cell 
epitope, facilitates protein interactions that result in self­
assembly of the Gag precursor (Ehrlich et al., 1992; Rose et 
al., 1992; Strambio-De-Castillia and Hunter, 1992). The 
importance of the MHR in capsid assembly is highlighted by the 
observation that it is conserved among all retrovirus core 
proteins (Patarca et al., 1985; Wills and craven, 1991). 
Close examination of the amino acid sequences of EIAV and 
HIV core proteins reveals several intriguing homologies. The 
first is a conserved pair of cysteine residues; specifically 
Cys198 and Cys218 of EIAV p26 with two cysteine residues in 
HIV-1 p24 (Figure 22). This raises the possibility of the 
presence of a conserved disulfide bridge, which, if present, 
could perform an important structural role in each of these 
proteins. The conservation of such a structural element would 
highlight an apparent necessity for the retention of this 
bond, suggesting i� performs an important function in the 
formation of subviral particles. 
A second interesting homology exhibited by these two 
proteins involves tryptophan residues. p26 from EIAV has 
three tryptophan residues (Trp23, Trp81 and Trp132), each of 
which is conserved in the primary sequence of p24 from HIV 
(Figure 22). The i�trinsic ability of tryptophan residues to 
fluoresce renders them useful for probing the structure of 
proteins. This con�ervation of tryptophan residues enables 
their fluorescence properties to be exploited in comparing the 
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structure of these two proteins. 
In light of the high degree of homology between the major 
core proteins of members of this family of viruses, we propose 
that structural information for p26 of EIAV may be applicable 
to other members of the Lentiviridae. It is particularly 
relevent to the major core proteins of FIV, HIV-1, and BIV, 
which collectively form a subfamily of the Lentiviridae 
exhibiting serological cross-reactivity of their major core 
proteins (Egberink et al., 1990; Goudsmit et al., 1986). A 
working knowledge of structural features, and ultimately the 
3-dimensional structure of capsid proteins provides important 
structural information which helps to develop an understanding 
of how the structure of these proteins is involved in their 
functionality. This is of particular interest with this family 
of proteins as they have been shown to be essential for viral 
infectivity. 
The high degree of amino acid similarity, combined with 
immunological cross reactivities, suggests that the 3-
dimensional structure of the lentiviral core proteins are 
likely to be related to some degree. At the present time, 
the structural information for lentiviral core proteins is 
limited to models assigned to HIV-1 core protein (p24). The 
models have been generated largely based on data generated 
from the mapping of antigenic determinants using monoclonal 
antibodies, in concert with computer-assisted structure 
predictions (Argos, 1989; Langedijk et al., 1990). The 
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computer generated model, proposed by Argos, indicates that 
p24 of HIV-1 is folded in the form of an anti-parallel beta­
barrel with a single stretch of alpha-helix. Langedijk and 
colleagues later assigned linear antibody binding sites to 
every turn and loop of the beta-barrel, and to the alpha­
helix. However, several antibody binding sites were also 
assigned to beta-sheet regions which one would not predict to 
be surface exposed, suggesting that the model may not be 
entirely accurate. These inconsistencies highlight the 
necessity for structural determinations of lentiviral core 
proteins which are based on experimental evidence rather than 
computer generated models. 
Diagnosing EIAV Infection 
The 'Coggins' test, which is an agar gel immunodiffusion 
assay, has been the accepted diagnostic for EIAV infection 
since it was developed almost 25 years ago (Coggins and 
Norcross, 1970). This assay detects antibodies to p26, the 
major core protein of EIAV, using protein which is purified 
from cell culture. The high relative abundance, 40% of total 
virion protein mass in EIAV, tied to the highly immunogenic 
and remarkably conserved nature of viral core proteins has 
made them popular choices in diagnostic assays for detecting 
viral infection. The use of retroviral envelope proteins for 
detecting viral infection is hampered by the rapid mutation 
rate of these proteins. Therefore, core proteins are generally 
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considered more reliable for capturing circulating antibodies. 
In the absence of a source of recombinant full-length 
protein, peptides or fusion proteins which incorporate major 
antigenic determinants are popular choices for creating 
diagnostic 
antibodies 
assays. Inhibition assays using monoclonal 
are also widespread. However, both of these 
approaches have potential shortfalls. Peptides and fusion 
proteins often fail to mimic antigenic sites to a sufficient 
degree, particularly if the sites are discontinuous in nature; 
while inhibition assays are at the mercy of a single amino 
acid substitution. Such a mutation is often sufficient to 
destroy the monoclonal antibody binding site resulting in a 
failure to detect infected samples. The latter is exemplified 
by the recent discovery of hepatitis B virus 'escape mutants' 
which were not detected by a monoclonal antibody based assay 
directed at the surface protein of the Hepatitis B virus 
(Fujii et al., 1992). 
We propose that a source of recombinant p26 could have 
useful applications in the design of new diagnostic reagents 
for EIAV. This could possibly take the form of an ELISA, 
which would have many potential benefits over the rather time­
consuming and insensitive immunodiffusion assay. 
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SPECIFIC AIMS 
1. Clone, express and purify the major core protein (p26) of 
EIAV using an E.coli expression system. 
2. Study the structural and physical properties of this 
protein and in the process evaluate it as a model for 
understanding lentiviral core proteins, particularly p24 from 
HIV-1. 
3. Develop a rapid and sensitive ELISA for detecting anti-p26 
antibodies in serum, and determine it's potential to serve 
as a marketable diagnostic assay for monitoring EIAV 
infection. 
BACKGROUND 
Cloning Strategy 
The cloning of the EIAV core gene, such that it does not 
include extraneous amino acids at the amino-terminus, requires 
the 'engineering' of the sequence around the initiator 
methionine residue. A popular choice for overcoming this 
problem is the incorporation of methionine-containing 
restriction sites at the 5' end of the gene (e.g. Nco!, Ndei, 
Sphi). For p26, the incorporation of an Nco! restriction site 
requires the alteration of the 4th nucleotide in the gene from 
an adenine to a guanine, this changes the second triplet from 
ATA (Ile) to GTA (Val) (Figure, 23a and b). However, since 
valine and isoleucine both have aliphatic, hydrophobic side 
chains, we do not expect this conservative alteration to be 
of significance in terms of the global structure of the 
protein. 
Processing of the amino terminus of this protein would 
be expected in E. coli since the initiator methionine is 
followed by valine. The following amino acids; His, Gln, Glu, 
Phe, Met, Lys, Tyr, Trp and Arg, when located as the 
penultimate amino acid, appear to supress the removal of the 
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Figure 23: Cloninq Strateqy for p26. 
Panel A - Nucleotide sequence of the primers used to amplify 
the p26 gene. The 5' primer introduces an Nco! restriction 
site, while the 3' primer introduces a Hindi! restriction site 
and a termination codon. Panel B - Alignment of the 5' ends 
of the original and cloned p26 sequences. Panel C - Alignment 
of the 3 ' ends of the oriqinal and cloned p26 sequences. 
Restriction sites are underlined (Nco! - CCATGG; Hindiii -
TTCGAA), and 'TAA' is a termination codon. 
A 
B 
c 
5'-GCCCATGGTAGATGGGGCTGGAAACAG -- 5'Ncoi Primer 
5'-CGAAGCTTAAAGTGCTTTTGCCAATAACAT -- 3'Hindiii Primer 
Original 
Cloned 
Original 
Cloned 
p I M I D G A G 
CCA ATC ATG ATA GAT GGG GCT GGA 
CC ATG GTA GAT GGG GCT GGA 
M v D G A G 
A A L Q T G L 
GCA AAA GCA CTT CAG ACT GGT CTT 
GCA AAA GCA CTT TAA GCT TCG 
A A L * 
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initiator methionine (Hirel et al., 1989). 
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Since the 
initiator methionine would be expected to be removed on 
this protein, valine is a good choice as the penultimate 
amino acid according to the 'N-end rule' proposed by Tobias 
and coworkers (Tobias et al., 1991). They reported protein 
half-lives of only 2 minutes when the following amino 
acids were present at the amino terminus; Arg, Lys, Phe, 
Leu, Trp, and Tyr. 
The Gag precursor of EIAV is synthesized as a 
polyprotein, meaning that p26, which is flanked by p15 (matrix 
protein) and p11 (nucleocapsid protein) (Figure 21), does not 
contain a termination codon. Therefore it was necessary to 
insert a termination codon at the predicted 3' end of the 
cloned p26 gene (Stephens et al., 1986). This was achieved by 
inserting a termination codon immediately upstream of the 
Hindi!! cloning site in the reverse PCR primer (Figure 23c) . 
Predicted Features of p26 
The predicted length of the equine infectious anaemia 
major core protein is 233 amino acids (Figure 22). The core 
protein in this study is expected to be 231 amino acids long 
due to the fact that is starts at the first methionine 
residue, where an Nco! restriction site could be conveniently 
inserted (Figure 24). Therefore, our clone lacks the first two 
amino acid, proline and isoleucine (Figure 22). When refering 
to specific amino acids, numbering is done in accordance with 
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3 MVDGAGNRNF RPLTPRGYTT WVNTIQTNGL LNEASQNLFG ILSVDCTSEE 
53 MNAFLDVVPG QAGQKQILLD AIDKIADDWD NRHPLPNAPL VAPPQGPIPM 
103 TARFIRGLGV PRERQMEPAF DQFRQTYRQW IIEAMSEGIK VMIGKPKAQN 
153 IRQGAKEPYP EFVDRLLSQI KSEGHPQEIS KFLTDTLTIQ NANEECRNAM 
203 RHLRPEDTLE EKMYACRDIG TTKQKMMLLA KAL* 
Figure 24: Amino acid Sequence of Cloned EIAV Core Protein. 
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the predicted full-length protein, the sequence of which is 
displayed in figure 22. Thus, the initiator methionine of the 
p26 clone is in fact residue 3. 
Successful expression of the gene constructed in this 
study is predicted to yield a protein with a molecular weight 
of 2 6kDa. There are no predicted sites of glycosylation 
on this protein. It has an isoelectric point of 6.78, which 
means that the protein would be expected to carry zero net 
charge at this pH. The extinction coefficient for this 
protein is calculated to be 22,370 M-1cm-1• 
MATERIALS AND METHODS 
Cloning of the EIA V Core Gene 
Isolation of Viral RNA from EIAV Infected Serum 
Total RNA was prepared from EIAV infected serum using the 
procedure described by Simmonds (Simmonds et al., 1990), with 
minor alterations, including those described by Castillo 
(Castillo et al., 1992). To 200J.Ll of serum, 500J,Ll of a 
solution containing 4. 2M guanidine thiocyanate, 0. 5% sarkosyl, 
25mM sodium citrate, pH 7.0, and 5J,Ll of 2-mercaptoethanol were 
added. The solution was mixed and 50J.Ll 2M sodium acetate 
(pH4.0), 500J.Ll phenol, and 200J.Ll chloroform were also added, 
the samples were mixed and incubated for 15 minutes on ice. 
After centrifugation at 14,000xg for 15 minutes at 4°C, the 
aqueous phase was twice re-extracted with chloroform. The 
viral RNA was precipitated with isopropanol at -70°C 
overnight. Next morning the RNA was pelleted by centrifugation 
at 14,000xg for 30 minutes at 4°C, washed with 70% ethanol, 
and dried. The pellet was resuspended in 3J.Ll of TE buffer 
(10mM tris-Cl, pH 8.0, 1mM EDTA), and used as the template for 
the reverse transcription reaction. 
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Reverse Transcription and PCR Amplification 
The reverse transcription reaction was prepared according 
to the manufacturer's directions ('GeneAmp', Perkin, Elmer & 
Cetus). The total reaction volume was 20!-£1 and random hexamers 
(2.5!-£M) were used to prime the reaction. Following a 10 minute 
incubation at 25°C the mixture was incubated at 42°C for 20 
minutes, 99°C for 5 minutes, and finally 4°C for 5 minutes. The 
contents of this tube were then used as the template for a 
standard PCR reaction. The following conditions were employed 
for the PCR; 5 cycles of 94°C, 42°C and 72°C, each for 1 
minute; followed by 35 cycles of 94°C, 55°C and 72°C, each for 
1 minute. A final 'filling-in' step of 72°C for 5 minutes was 
incorporated to assure that the ends of the PCR product were 
'flush'. The product of the PCR reaction was run on an 
agarose gel (0.8%), and a 712bp product was extracted using 
the 'Qiaex' DNA extraction kit (Qiagen). 
Restriction Digestion and Cloning 
The primers used for the PCR were designed such that the 
product had an Nco! restriction site at the 5' end, and a stop 
codon followed by a Hindi!! restriction site at the 3' end 
(Figure 23). Two additional nucleotides were incorporated 5' 
of the restriction sites to facilitate efficient cutting of 
the PCR product by these enzymes. 
The 712bp PCR product was digested with the restriction 
enzymes Nco! and Hindi!! and cloned into the vector pUC18N, 
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which had been cleaved with the same two enzymes. pUC18N is 
identical to pUC18 except it has an Nco! restriction site 
introduced at the 5' end of the multiple cloning site (Zheng 
et al., 1992). A positive clone was identified by restriction 
analysis of mini-prep DNA and ultimately by automated DNA 
sequencing. 
To express EIAV core protein the gene was cloned into the 
expression vector pKK332 (Pharmacia), which uses the 'tac' 
promotor to drive the expression of cloned genes. The 
initiator methionine residue is coded for by the ATG triplet 
within the Nco! restriction site, ensuring that no extraneous 
amino acids are incorporated into the final gene product. 
The Ncoi/Hindiii fragment bearing the core gene was 
excised from pUC18N/EIAp26 and ligated into the Ncoi/Hindiii 
sites of the expression vector. The host cell strains used for 
expression were TB1. 
DNA Sequencing 
The identity of the cloned DNA was confirmed by automated 
DNA sequencing of pUC18N/EIAp26, performed by the 'MCV-VCU 
Nucleic Acid Core Facility'. 
site-Directed Mutagenesis of cysteine-48 to Serine 
A two-step PCR reaction was used to mutate cysteine-46 of 
EIAV core protein to a serine. Two mis-match oligonucleotide 
primers were designed such that base number 142, a thymidine, 
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was mutated to an adenine. This changes codon number 48 from 
'TGT' which specifies cysteine, to 'AGT' which specifies 
serine. This single nucleotide mutation also results in the 
introduction of a new and unique restriction site (Seal). This 
is a necessary feature of the mutagenesis procedure (Figure 
25) • 
Two PCR reactions were carried out using pKK322/ElAp26 as 
the template, and the following pairs of primers: 
1. 5' Ncol primer (forward), and the internal mis-match Seal 
primer (reverse). 
2. 3' Hindlll primer (reverse), and the internal mis-match 
Seal primer (forward). 
The products of the two reactions, an NcoljScal fragment 
corresponding to the 5' end of the gene, and a Scal/Hindlll 
fragment corresponding to the 3' end of the gene were 
recovered and digested with Seal. The two fragments were 
ligated to create the mutated gene, and then used as the 
template for a third PCR reaction. The final PCR reaction, 
using the original 5' Ncol and 3' Hindlll primers, served 
merely to amplify the mutant gene to acquire sufficient DNA 
for successful cloning. The final product was digested with 
Ncol and Hindlll, and then ligated into pKK322. The 
identity of the final clone was confirmed to be that of the 
Cys48Ser mutant by confirmation of the presence of the Seal 
restriction site. 
A 
B 
5'- ACAGTACTTCTGAAGAAATGAATGC -3' 
5'- GAAGTACTGTCTACTGATAATATCCC -3' 
Original 
Cys48Ser 
V D C  T S E 
... GTA GAC TGT ACT TCT GAA .. . 
... GTA GAC AGT ACT TCT GAA .. . 
V D S T S E 
Figure 25: Mutation of Cysteine 48 to Serine. 
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Panel A shows the sequence of the Scai primers used to PCR 
amplify the two gene fragments. Scai restriction sites are 
underlined. Panel B shows the original and mutated gene 
sequences. Amino acid sequences are shown in bold, and the 
Scai restriction site in the cys48Ser mutant is underlined. 
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Deletion of the Hydrophobic Carboxyl-Terminus of p26 
The hydrophobic carboxyl-terminus of p26 was deleted by 
designing a PCR primer which terminated the translation of the 
protein after Lys223 (Figure 26). This primer was used in 
combination with the original Ncoi primer, in a PCR reaction 
where pUC18N/p26 served as the primer. The PCR product was 
cloned into the pKK322 expression vector. 
Expression and Purification of EIA V Core Protein 
Expression of EIAV core protein 
E. coli (strain TBl) was transformed with the plasmid 
pKK/EIAp26 and plated onto an LB plate supplemented with 
50�g/ml ampicillin. A single colony was selected and used to 
inoculate lOOml of TYN media (lOg tryptone, lOg yeast extract, 
5g NaCl, pH 7.4), supplemented with lg/L glucose and 50�g/ml 
ampicillin. This culture was grown for 8 hours at 37°C and 
then used to inoculate lOL of the same media. This culture was 
grown for 24 hours, after which time the cells were harvested 
by centrifugation at 6000 rpm for 5 minutes. Cell pellets were 
stored at -70°C until needed. 
Purification of EIAV Core Protein - Method 1 
Cell pellets were resuspended in water (30ml/L of cells) 
and lysed by a single passage through a French pressure cell 
at 12,500psi. The cell lysate was clarified by centrifugation 
at 20,000rpm for 30 minutes, and the supernatant was brought 
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G T T K Q K M M L L A K A L * 
GGA ACT ACA AAA CAA AAG ATG ATG TTA TTG GCA AAA GCA CTT TAA 
GGA ACT ACA AAA CAA AAG TGA TAA GCT T 
G T T K Q K * * 
Figure 26: Deletion of the Carboxyl-Terminal Hydrophobic 
Reqion of p26. 
The carboxyl-terminal 8 amino acid of p26 were deleted in an 
attempt to increase the solubility of the protein for 
crystallization experiments. The sequence of the oriqinal p26 
clone is shown above the truncated mutant. The Hindi!! 
restriction site (AAGCTT) is underlined. Two stop codons were 
included in another attempt to decrease heteroqeneity at the 
carboxyl-terminus of the protein. 
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to a 50% ammonium sulfate saturation by the addition of solid 
ammonium sulfate (313g/L). The precipitate was recovered by 
centrifugation at 20,000 rpm for 10 minutes and resuspended in 
lOmM sodium phosphate, pH 6.8, before being dialyzed against 
the same buffer at 4°C, overnight. The dialyzed protein was 
applied to a hydroxyapatite column which had previously been 
equilibrated with lOmM sodium phosphate, pH 6. 8. Once the 
protein had entered the column it was washed extensively with 
50mM sodium phosphate, pH 6.8. The eluent was collected until 
the optical density, measured at 280nm, fell below 0.1. The 
eluent was subjected to a second 50% ammonium sulfate 
precipitation. The precipitate was recovered in the manner 
described previously, resuspended in lOmM tris-Cl, pH 8.0, 
and dialyzed against the same buffer at 4°C, overnight. The 
protein was loaded onto a DE-51 column (Whatman), which had 
been equilibrated with lOmM tris-Cl, pH 8.0. Bound proteins 
were eluted with a linear gradient of 0-300mM NaCl in the same 
buffer. Fractions were assayed for core protein, using the 
inhibition ELISA assay described (see below), pooled, and 
subjected to a 50% ammonium sulfate precipitation. The 
resultant precipitate was recovered by centrifugation, 
resuspended in a minimum volume of lOmM tris-Cl, pH 8.0, and 
dialyzed against the same buffer overnight. The material was 
then loaded onto a Biegel p-100 sizing column (2.5 x lOOcm) 
which had been equilibrated in lOmM tris-Cl, pH 8. 0. 5ml 
fractions were collected and assayed for core protein. Active 
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fractions were pooled and its purity tested by SDS-PAGE. 
Purification of EIAV Core Protein - Method 2 
The second purification procedure was identical to 
'method 1' in it's initial stages. However, following the 
first 50% ammonium sulfate precipitation, the protein was 
dialyzed against 50mM sodium phosphate, pH 6. 8, and applied 
to a DE-52 anion exchange column {Whatman) which had 
previously been equilibrated with the same buffer. Once the 
protein had entered the column it was washed extensively with 
50mM sodium phosphate, pH 6.8. The eluent was collected, and 
subjected to a second 50% ammonium sulfate precipitation. The 
precipitate was recovered, resuspended in a minimum volume of 
50mM sodium phosphate, pH 6. 8, and dialyzed against the same 
buffer overnight, at 4°C. The solution was clarified by 
centrifugation {18,000xg, 20 min), and loaded onto a p-100 
sizing column (Biegel). Fractions {20ml) were collected and 
assayed for core protein. Active fractions were pooled and 
purity tested by SDS-PAGE. 
Physical and Chemical Characterization of EIA V Core Protein 
SDS-PAGE 
Analytical polyacrylamide gel electrophoresis was 
performed according to the method of O'Farrell {O'Farrell, 
1975). 4% acrylamide stacking gel and 15% acrylamide 
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resolving gel were employed. 
Immunoblotting 
Immunoblotting was performed according to the method of 
Burnette (1981). Briefly, membranes were blocked with 4% BSA 
in PBS, and 1:50 dilutions of horse serum were made in 1% BSA 
in PBS. The serum was incubated with the membrane at room 
temperature, overnight. A 1:3,000 dilution of anti-horse IgG 
peroxidase (Sigma) was made in PBS and incubated with the 
membrane for 1 hour. 
chloronapthol/H202• 
The immunoblots were developed with 
Amino-Terminal Sequence Analysis 
5�g of pure p26 protein were subjected to amino terminal 
sequencing. Five cycles of sequence analysis were performed 
using an Applied Biosystems model 470A sequencer, equipped 
with an in-line PTH-amino acid analyzer. 
Circular Dichroism Spectroscopy 
Circular dichroism spectra were generated on a Jobin Yvon 
Mark III dichograph using a 0.1cm path-length quartz cell. The 
protein concentration was 0.1mgfml. The values of mean M,. 
residue ellipticities were calculated on the basis of 110 as 
the average M,. per residue and they are reported in terms of 
[ 0) m.r.w. (degrees. cm
2
• dmol-1) • The secondary structure estimations 
were performed by computer fit according to the ellipticity 
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reference values of Bolotina et al. (1980), which are based on 
proteins of known three-dimensional structure. 
Fluorescence Spectroscopy 
Fluorescence studies were carried out with a Perkin-Elmer 
MPF-44E spectrofluorimeter fitted with a 150W xenon arc and a 
differential correction spectra unit (DCSU-2). The temperature 
in the cuvette was maintained by a Lauda circulating water 
bath. Excitation was performed at a wavelength of 275nm, and 
emission spectra measured over a range of 280-450nm. 
Quenching studies were performed by adding aliquots of 
a stock solution of 2M KI, containing 0. 1mM Na2S203 to prevent 
!3- formation. The data from a control experiment performed 
with 2M NaCl instead of KI, in order to mimic the ionic 
strength and protein concentration, was subtracted from the 
quenching data. The analysis of quenching was performed 
according to a modified form of the Stern-Volmer relationship: 
F0/ (F0-F) 
= 
1/ ( [Q) f.K.) + 1/f. 
where F0 is the fluorescence in the absence of quencher, F is 
the fluorescence at a molar quencher concentration [QJ, K. is 
the Stern-Volmer constant and f. is the fraction of 
fluorescence accessible to the quenching agent (Lehrer, 1971). 
From a plot of F0/F0-F) versus [Qr1, the values of f. and K. can 
be calculated. At each quencher concentration, F0 was 
determined from a p26 solution to which aliquots of 2M NaCl 
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were added. 
Free-Cysteine Labelling 
The free cysteine residue was labelled with 14C­
iodoacetamide in the presence of 6M guanidine hydrochloride. 
After removal of the excess 14C-iodoacetamide the protein was 
reduced and alkylated again, this time with unlabelled 
iodoacetamide. The reduced and alkylated protein was digested 
with trypsin. Separation of the tryptic peptides was achieved 
by fractionation using reverse phase HPLC. An 'Ultrasphere 
ODS column' was used, along with a linear gradient (0-30%, 80 
min). Fractions were 'counted' in a Beckman liquid 
scintillation counter, and those containing radioactivity were 
hydrolysed with 6N HCl, at 115°C for 24 hours, and analyzed 
using a Beckman 6300 amino acid analyzer. 
Free Thiol Titration 
The free sulfhydryl content of p26 was determined using 
Ellman's reagent (5,5'-dithiobis-2-nitrobenzoic acid, Sigma), 
under both native and denaturing conditions (Ellman, 1958; 
Riddles et al., 1979). To measure the number of surface 
accessible sulfhydryl groups, a solution comprised of 40�M 
Ellman's reagent and 100mM Na2HP04 was mixed 1:1 with pure p26 
protein (2mg/ml) in lOOmM Na2HP04• The reaction was 
supplemented with 0.1% SDS for the determination of 'total' 
free sulfhydryl groups. The reaction was allowed to proceed 
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at 37°C, for 10 minutes, after which time the absorbance was 
measured at 412nm. The free sulfhydryl concentration was 
calculated using the extinction coefficient of 13,600 cM-1M-1• 
A prior knowledge of the exact protein concentration 
facilitated the determination of the number of surface 
accessible, as well as total free, sulfhydryl groups present 
in the protein. 
Crystallization 
The ability of purified EIAV core protein to crystallize 
was investigated using a commercially available kit comprised 
of 50 different buffer/salt/precipitant mixtures ('Crystal 
Screen', Hampton Research), using the 'hanging drop' technique 
described in the accompanying directions. One milliliter of 
purified core protein (16mg/ml) was dialyzed against 1mM 
sodium phosphate overnight. Briefly, 2�1 of each of the 50 
crystal screen buffers was mixed with 2�1 of protein, applied 
to a siliconized coverslip, inverted, and sealed with vacuum 
grease above 0. 5ml of the same buffer (undiluted). The 50 
samples were set-up in duplicate; one series was incubated at 
4°C and the other at room temperature. 
IMMUNOASSAYS 
Conjugation of Core Protein to Horseradish Peroxidase 
A p26-peroxidase conjugate was prepared by reacting 2mg 
of pure p26 protein with 1mg of activated horseradish 
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peroxidase in 50mM sodium phosphate buffer, pH 7. 0, 50mM 
sodium cyanoborohydride at 37°C for 1 hour. The conjugate was 
stable for at least 6 months when stored at 4°C. 
ELISA for Detecting EIAV Core Protein 
Purified p26 protein was coated to the wells of 
microtitre plates (Costar) by incubation at room temperature, 
overnight, at a protein concentration of 10�g/ml (50�1 per 
well) in 50mM sodium bicarbonate buffer, pH 9.2. Next morning 
the plates were blocked with 1% BSA for 1 hour at room 
temperature, dried, and stored at -20°C until needed. 
EIAV positive horse serum was diluted (1: 10) with normal 
horse serum. 50�1 of this was added to each well of a 
microtitre plate, which had previously been coated with p26 
protein, and incubated for 10 minutes. The wells were then 
washed and 50�1 of the sample to be assayed for core protein 
was added to each well. After 5 minutes, 50�1 of p26 
peroxidase conjugate (1:1000 dilution) was added to each well. 
Five minutes later the wells were washed and 50�1 of 'TM Blue' 
substrate (TSI) was added. After 10 minutes the reaction was 
stopped by the addition of 100�1 lN sulfuric acid and the 
plates read at a wavelength of 450nm. Typically, wells which 
had not received core protein gave an absorbance of 0.8 to 1.2 
whereas those with core protein were significantly lower at 
0.1 to 0.4 absorbance units. Fractions exhibiting inhibition 
of 50% or more were considered positive for p26 protein. All 
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steps were carried out at room temperature. 
ELISA For Detecting EIAV Infection 
To assay for anti-core antibodies, 50�1 of serum was 
added to each well of microtitre plates, which had previously 
been coated with p26 protein, and incubated at room 
temperature for 30 minutes. The wells were then washed and 
50�1 of p26-peroxidase conjugate (diluted 1:1000 in normal 
horse serum) was added to each well. Following a 15 minute 
incubation the wells were washed again and 50�1 of 'TM Blue' 
substrate was added. The reaction was allowed to proceed for 
10 minutes, after which time it was stopped by the addition of 
100�1 1N sulfuric acid and read at a wavelength of 450nm. All 
steps were performed at room temperature. 
Generation of Polyclonal Rabbit Antisera 
100�1 of p26 protein (1mgjml) was diluted to 500�1 with 
PBS and mixed 1:1 with Freund's complete adjuvant (Sigma). 
Following brief sonication the homogenous emulsion was 
administered to a single New Zealand white rabbit by making 
multiple injection, subcutaneously, on the back of the rabbit. 
One month later the rabbit was 'boosted' by injecting antigen 
in a similar manner, except that the antigen was mixed 1:1 
with Freund's incomplete adjuvant. This procedure was repeated 
after two weeks, and one week later the rabbit was 
sacrificed. 
RESULTS 
Cloning, Expression and Purification of EIA V Core Protein 
The gene coding for the major core protein {p26) of the 
lentivirus EIA was successfully reverse transcribed from viral 
RNA which had been extracted from infected serum, amplified by 
PCR, and cloned. The gene, whose identity was confirmed by 
automated DNA sequencing, was then cloned into pKK322, an 
E.coli expression vector. The protein, expressed in a soluble 
form, was subsequently purified using standard biochemical 
procedures {Figure 27). The final preparation was determined 
to be >95% pure by SDS-PAGE analysis {Figure 27, Lane 6). 
Approximately 50-BOmg of p26 protein was routinely purified 
from 20 liters of culture. 
Chemical and Physical Characterization of EIA V Core Protein 
Amino-Terminal Sequence Analysis 
The identity of the purified protein was confirmed by 
amino-terminal sequence analysis {Table 3). The first five 
residues were determined to be Val, Asp, Gly, Ala, Gly, 
which is consistent with residues 2 through 6 of the published 
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sequence (Kawakami et al., 1987). The endoproteolytic cleavage 
of the initiator formyl-methionine (fMet) residue, which is 
catalyzed by methionyl aminopeptidase, is frequently reported 
when proteins are expressed and purified from E.coli. Since 
the penultimate amino acid of p26 is valine, removal of the 
amino-terminal fMet would be expected according to the 
observations of Hire! et al. (1989). 
Ultra-Violet Spectroscopy 
When analyzed by ultra-violet spectroscopy, purified p26 
exhibited absorption spectra characteristic of a soluble 
protein (Figure 28). It exhibited maximum absorbance at a 
wavelength of 280nm, suggesting that it does not have an 
affinity for nucleic acid. 
Reducing and Non-Reducing SDS-PAGE Analysis 
Pure EIAV core protein was subjected to SDS-PAGE analysis 
in both the presence and absence of reducing agent (5% 2-
mercaptoethanol), in order to determine if it contained any 
intermolecular disulfide bridges. The results, displayed in 
figure 27, show that no intermolecular disulfide bridges are 
present. Under either reducing (lane 6), or non-reducing 
conditions (lane 7), the protein migrates as a monomer of 
26kDa. This observation does not exclude the possibility that 
the protein has an intramolecular disulfide bond. 
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1 2 3 4 5 6 M 7 
- p26 
Figure 27: SDS-PAGE to Show the steps in Purification of EIAV 
Core Protein. Lane 1: Cell Lysate; Lane 2: 50% ammonium 
sulfate precipitate; Lane 3: hydroxyapatite eluent; Lane 4: 
50% ammonium sulfate pellet; Lane 5: DE-51 fractions; Lane 6: 
P-100 pooled fractions; Lane 7: P-100 pooled fractions (non­
reducing); M = molecular weight markers, 97.4, 66.2, 55.0, 
4 2 . 7 , 4 0 . 0, 31. 0, 21 . 5, 14 . 4 kDa. 
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Table 3: Amino-Terminal sequence Data (5 cycles). 
The most abundant amino acid at each cycle is indicated with 
bold type. Units are in picomoles. 
CYCLE NUMBER 
1 2 3 4 5 
Val 15.30 1.88 0.90 0.79 0.00 
Asp 0.00 8.67 6.11 1.97 0.79 
Gly 6.6 6  3.81 25.57 9.6 6  23.51 
Ala 8.07 7.09 6.07 33.56 11.6 6  
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Since p26 contains 3 cysteine residues (Figure 22), it must 
adopt one of two possible disulfide bonding patterns: either, 
it must have a single intramolecular disulfide bridge along 
with a single free cysteine, or it must have 3 free 
cysteines. 
Determination of the Disulfide Bonding Pattern 
Using Ellman's reagent it was possible to ascertain both 
the number of free sulfhydryl groups, in addition to their 
surface accessibility. The data, shown in table 4, suggest 
that EIAV core protein contains a single free cysteine 
residue. This is evident from the fact that one mole of p26 
reacts with one mole of Ellman's reagent. Further, this single 
reactive cysteine must be poorly accessible to solvent since 
it reacts only poorly when the protein is in its native 
conformation. However, when the protein is denatured by 
treatment with SDS the cysteine is fully exposed. 
The fact that p26 contains only a single reactive 
cysteine residue, even when denatured by the presence of sos, 
suggests that the other two cysteine residues must form a 
disulfide bridge. This accounts for their lack of reactivity 
with Ellman's reagent. 
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Figure 28: Ultra-violet Absorption spectra for p26. 
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In an attempt to ascertain which of the three cysteine 
residues was free and which two were involved in forming the 
disulfide bond, the protein was reacted with iodoacetic acid 
e4C) 
· Digestion of the labelled protein with trypsin and 
separation of the peptides by HPLC resulted in the 
identification of three fractions associated with 
radioactivity (Figure 29). Each of the three peptides was 
identified by amino acid analysis, and it was shown that the 
three reactive peptides contained a cysteine residue. The 
counts per minute per nanomole (cpmjnmol) of cysteine was 
determined for each peptide in order to determine the 
relative amounts of 14C label associated with each of the three 
cysteine residues. The results are displayed in figure 30. 
Two-thirds of the radioactivity (14,100 cpm/nmol) was 
associated with peptide 1, which contained cys-48, suggesting 
that it is the free cysteine in p2 6. The other cysteine 
containing peptides were also associated with radioactivity, 
although to a much lesser extent. The Cys-198 containing 
peptide had 5070 cpmjnmol, and the cys-218 containing peptide 
had 2020 cpmjnmol. The reactivity of these residues could 
result from reduction of the disulfide bond during storage, or 
the formation of a partial disulfide bond. The latter is 
unlikely because newly purified protein reacted with Ellman's 
reagent with a stoichiometry which indicated the presence of 
exactly one mole of free cysteine residues per mole of 
protein. 
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Ta�le 4: Free Thiol Determination of p26 
All determinations were done in triplicate and the protein 
concentration was 34.41�M. 
Protein SDS A412 [React.Cys)�M 
- - 0.079 0 
+ - 0.164 6.25 
- + 0.035 0 
+ + 0.517 35.44 
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t (min, 
Fiqure 29: HPLC Elution Profile of Trypsin Digested, 
carboxymethylated (14C) and Reduced p26. The three peaks 
associated with the radioactive label are indicated. 
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Figure 30 Quantitation of 14C Labelled Peptides. 
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To more precisely determine whether cys-48 is indeed the 
'free' cysteine in p26, a mutant was constructed whereby this 
residue was substituted for a serine. The mutant protein was 
purified using the same purification procedure described for 
the wild-type protein. The reactivity of the Cys48Ser mutant, 
in comparison with wild type p26, with Ellman's reagent was 
determined and the results are displayed in table 5. It is 
apparent from these experiments that Cys-48 is indeed the free 
cysteine residue in p26. The mutant form of p26, which 
contains a serine at amino acid 48, is no longer reactive 
toward Ellman's reagent. Further, this indicates that Cys-181 
and Cys-213 are connected by an intramolecular disulfide bond. 
Circular Dichroism Spectroscopy 
Circular dichroism spectroscopy of p26 in the 'far' UV 
(Figure 31), revealed that the protein exhibits a high content 
of alpha-helical structure (Table 6). This is in close 
agreement with the values predicted for this protein using the 
algorithms of Chou-Fasman (Table 6). Further, reduction and 
carboxymethylation of p26 causes a significant alteration in 
the CD spectrum of p26 (Figure 31), which is indicative of 
significant structural changes in the protein (Table 7). 
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Table 5: Free Thiol Determination of Wild-Type p26 Versus the 
Cys48Ser Mutant. (TNB, thionitrobenzene). 
Protein [Protein],LLM A410nm [TNB],LLM Free cysfmol 
Wild Type 34.26 0.47 34.50 1. 01 
Cys48->Ser 35.45 0.00 0.00 o.oo 
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Figure 31: Circular Dichroism Spectra of p26. Far uv spectra 
were generated over a wavelength of 200-250nm using a protein 
concentration of O.lmgfml. 
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Table 6: Predicted Versus Actual Secondary Structure 
comparison. 
Predictions were made using the algorithms of Chou-Fasman. 
Prediction Actual 
Alpha Helix 46% 40% 
Beta Sheet 24% 22% 
Beta Turn 12% 10% 
Random Coil 18% 28% 
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Table 7: Native versus ReducedfCarboxmethylated Secondary 
structure Comparison. 
Native p26 CAM p26 
Alpha Helix 40% 42% 
Beta Sheet 22% 26% 
Beta Turn 10% 0% 
Random Coil 28% 32% 
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Fluorescence Spectroscopy 
The emission spectra for native p26 shows a maximum at 
337. 5nm, indicating the presence of a major population of 
tryptophan residues, along with a less well-defined peak at 
327. 5nm (Figure 32). This is indicative that their two 
different populations of tryptophan residues, and inferences 
can be made regarding differences in the environment around 
the tryptophan residues. As a reference, tryptophan which is 
free in solution has a emission maximum at 348nm, whereas a 
tryptophan residue which is completely buried in a 
hydrophobic environment has emission maximum at 310-320nm. 
Accordingly, one can infer that the major population of 
tryptophan residues in p26, which emit at 337.5nm, are 
situated in a less hydrophobic environment than the smaller 
population of tryptophan residues emiting at 327.5nm. In this 
form, the technique does not allow for the assignment of 
individual tryptophan residues, but it is logical to suggest, 
because p26 contains only 3 tryptophan residues, that 2 of the 
tryptophans account for the emission maximum (337.5nm), while 
the remaining one accounts for the smaller maximum at 327.5nm. 
In contrast, the reduced and carboxylmethylated protein 
exhibits a maximum at 325 and a less well-defined maximum at 
337.5nm (Figure 32). The shift in fluorescence maxima to a 
lower wavelength upon reduction and carboxylmethylation of 
p26 is indicative of a change in the environment of the 
tryptophan residues. Specifically it suggests that the major 
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Fiqure 32: Fluorescence Spectra 
ReducedfCarboxymethylated p26. 
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and 
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population of tryptophan residues are in more hydrophobic 
environment in the modified protein compared with that 
experienced by the same tryptophan residues in the native 
protein. 
Iodide Quenching of Protein Fluorescence 
The modified Stern-Volmer plot for both native and 
carboxyamidomethylated p26 is shown in figure 33. From this 
plot, the following results were obtained: 
-Native p26 : Fa = 0.86 
-carboxiamidomethylated p26 : Fa = 0.33 
(Fa : Fraction of fluorescence accessible to the quenching 
agent) . 
The results obtained in this experiment are in 
concordance with those from the circular dichroism and 
fluorescence studies, i.e. the protein has a higher degree of 
ordered structure when the disulfide bridge is reduced, 
because, in accordance with the Fa values, the accessibility 
of the fluorophore to iodide is diminished. Since iodide is 
charged (anionic) and highly hydrated, it will only interact 
with those flurophores at or near the surface of the protein. 
Therefore, the carboxyamidomethylated protein appears to have 
more tryptophan residues buried in a hydrophobic environment. 
This confirms the observations seen with the fluorescence 
spectra. 
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Figure 33: Modified Starn-Volmer Plot to Show the 
Fluorescence Quenching of Native and Reduced/Carboxymethylated 
p26. 
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Crystallization of EIAV Core Protein 
EIAV p26 core protein, purified using method one, was 
successfully crystallized in only one of the 50 different 
buffer/precipitant/salt conditions tested. The successful 
reagent (#7) contains O.lM sodium cacodylate, pH 6.5, and 1.4M 
sodium acetate trihydrate. crystal growth was reproducibly 
observed when grown at 4°C, but not at room temperature, and 
they exhibited a parallelepiped appearance (Fig. 34a and b). 
In an attempt to further refine the crystallization 
conditions the effects of varying the concentration of sodium 
acetate trihydrate was investigated. It was found that either 
increasing, or decreasing the acetate concentration in the 
drop prevented crystal growth. While increasing the acetate 
concentration from 0. 7 to 1. OM caused aggregation of the 
protein, decreasing it to 0. 4M resulted in an absence of 
crystal formation. 
Varying the pH of the crystallization buffer seemed to 
have a somewhat less dramatic effect on the growth of the 
crystal. Crystals of a similar form to those observed in the 
original buffer were successfully grown over a pH range of 
6.0-7.5. However, pH values below 6.0 caused precipitation of 
the protein. 
Purification of p26 using method two appeared to yield 
a form of p26 which was not proteolytically cleaved. However, 
attempts to crystallize this protein, using the established 
crystallization conditions for p26, failed. Instead of 
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Figure 34: Parallelopiped-Like crystals of BIAV Core Protein. 
Magnification is xlOO (Panel A), and x200 (Panel B). 
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crystallizing, the protein precipitated, suggesting that it is 
less soluble than the material purified using purification 
scheme one. 
Immunological Studies of EIA V Core Protein 
Immunoblotting with EIAV Infected Serum 
Immunoblotting of purified p26 protein with sera which 
was either positive or negative for EIAV infection, confirmed 
that p26 binds antibodies which are specific to EIAV infected 
horses (Figure 35). The four nitrocellulose strips incubated 
with four different EIAV positive sera show a strong 
reactivity toward p26, while the two EIAV negative controls 
show no such reactivity. 
ELISA Sensitivity 
The relative sensitivity of the assay, as well as 
relative titres of anti-p26 antibodies, were assessed by 
assaying 3 randomly selected EIAV positive sera at logarithmic 
dilutions (Table 8) . All three samples were easily 
identifiable as being EIAV positive at a dilution of 10-1, 
and two were identifiable at a serum dilution of lo-2• 
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Figure 35: Immunoblotting with EIAV Infected serum. 
Lanes 1-4, EIAV infected serum; Lanes 5 & 6, normal horse 
serum. 
154 
Detection of EIAV Positive Sera by ELISA 
The ELISA successfully identified 30 known EIAV positive 
serum samples which had been selected randomly following field 
tests conducted in the state of Virginia (Table 9). A total of 
23 out of the 30 sera tested (72.6%) exhibited absorbance 
values of >2.0, while 
absorbance values of >1.0 
all 30 (100%) 
(Table 9). 
of the 
ELISA Analysis of a 'Blind Panel' of Horse Sera 
sera gave 
The immunoassay was tested for it's ability to 
differentiate between EIAV positive and EIAV negative sera in 
a 'blind panel' of 30 sera supplied by the National Veterinary 
Services Labs (Ames, Iowa). The results, displayed in table 10 
and figure 36, show that the ELISA successfully assigned all 
30 of the serum samples. All negative sera gave absorbance 
values which did not exceed 0.05, while all positive sera 
exhibited absorbance values of >0.5, a value which is greater 
than 10 times higher than the highest 'negative'. Of the 19 
positive sera, 18 (94.7%) exhibited reactivities of >1.0, a 
value >20 times the highest negative. Only a single serum 
sample (#30) gave a test result of less than 1.0; however, at 
greater than 10 times above the most reactive 'negative', it 
was still easily identifiable using this test. Serum sample 
#30, was confirmed by the 'National Veterinary Labs.' as 
having a very low titre of anti-p26 antibody. 
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Table s: Results of ELISA to Measure Anti-p26 Antibody Titres 
in 3 Different EIAV infected horses. (U, undiluted serum). 
Dilution 1 2 3 
10,000 0.009 0.138 0.012 
1,000 0.007 0.170 0.080 
100 0.690 0.821 0.057 
10 >2.0 >2.0 0.978 
u >2.0 >2.0 >2.0 
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Table 9: Anti-p26 ELISA Results for 30 EIAV Positive Sera. 
Samples were collected during random field tests in the 
state of Virginia. 
A450 No. 
0.00-0.09 0 
0.10-0.49 0 
o. 50-1.99 8 (27%) 
>2.00 22 (73%} 
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Table 10: Anti-p26 ELISA Results for a Panel of EIAV Positive 
and EIAV Negative Sera. 
The results shown in parentheses are those indicated by 
National Veterinary Services Labs (Ames, Iowa), the supplier 
of the panel. 
* Confirmed as the weakest positive by National Veterinary 
Service Labs. 
No. A450nm Result No. A450nm Result 
1 1.190 + ( +) 16 >2.0 + ( +) 
2 0.034 - ( -) 17 >2.0 + ( +) 
3 1. 520 + (+) 18 >2.0 + (+) 
4 >2.0 + ( +) 19 0.000 - ( -) 
5 >2.0 + ( +) 20 0.000 - ( -) 
6 0.037 - ( -) 21 0.013 - ( -) 
7 >2.0 + (+) 22 0.000 - ( -) 
8 0.018 - ( -) 23 >2.0 + (+) 
9 1. 667 + (+) 24 0.000 - ( - ) 
10 >2.0 + (+) 25 >2.0 + (+) 
11 0.000 - ( -) 26 >2.0 + ( +) 
12 >2.0 + (+) 27 0.000 - ( -) 
13 >2.0 + (+) 28 >2.0 + ( +) 
14 >2.0 + (+) 29 0.013 - ( - ) 
15 >2.0 + ( +) 30* 0.582 + (+) 
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Sample Number 
Figure 36: Plot of ELISA Data for EIAV Test Panel. 
DISCUSSION 
Equine infectious anaemia (EIA) virus represents a 
valuable animal model for studying the human immunodeficiency 
virus (HIV) . The two viruses share many common features which 
extend from conserved genomic organization to striking 
homologies at the amino acid level. This is highlighted by 
the 55% similarity, and 30% amino acid identity shared by the 
major core proteins of HIV and EIAV (Stephens et al., 
1986). 
The high degree of homology exhibited by p26 of EIAV and 
p24 of HIV-1 at the level of primary sequence would suggest 
that this similarity may extend to secondary and tertiary 
structural similarities. Indeed, three dimensional homologies 
between the two core proteins have been proposed as a result 
of previous studies conducted using a series of p26 fusion 
proteins. It was demonstrated that a region of 15 amino acids 
in p26 of EIAV, 10 of which are identical to p24 from HIV, 
defines an epitope which binds a particular monoclonal 
antibody which also binds to the core proteins of HIV-1, HIV-2 
and SIV (Chong et al., 1991). The existence of such an 
'interspecies determinant' lends further evidence to the 
usefulness of p26 as a model for understanding lentiviral core 
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proteins (Goudsmit et al., 1986). Understanding the structure 
and function of this family of proteins, which have important 
roles in virus morphology, has applications in anti-viral 
therapy and vaccine development (Wills and Craven, 1991) . 
In this report we detail the cloning, high-level 
expression, and purification of the major core protein (p26) 
of EIAV from E.coli. Our ability to isolate milligram 
quantities of this protein has enabled us to begin studying 
its structure and to evaluate it as a model for understanding 
lentiviral core proteins in general. Further, we have 
developed a diagnostic ELISA for capturing anti-p26 antibodies 
and have analyzed its suitability for detecting EIAV 
infection. 
The structure of p26 was studied using a variety of 
biophysical techniques, including circular dichroism and 
fluoresence spectroscopy. Circular dichroism data for p2 6 are 
not consistent with the models proposed by Argos (1989) for 
p24 of HIV. We propose that p26 has significantly more alpha 
helix (40%), than proposed for p24 (24% alpha helix), which 
has a single, short alpha helical region. our observation is 
indirectly supported by the data of Langedijk (1990), who 
observed that several antibody binding sites mapped to regions 
proposed to be beta sheet in the Argos model. The hydrophobic 
nature of beta sheet structure makes this highly improbable. 
These discrepancies may be due to legitimate structural 
differences between the two proteins. However, because of 
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their high degree of amino acid similarity and conserved 
function, it is highly probable that p26 from EIAV and p24 
from HIV-1 are structurally similar (Chong et al., 1991; Grund 
et al., 1994; Stephens et al., 1986; Goudsmit et al., 1986). 
In these studies, cysteine-48 of p26 was identified, 
using a combination of chemical modification and site-directed 
mutagenesis, as being a free cysteine residue. Interestingly, 
this residue is not conserved in the p24 from HIV (Figure 22), 
suggesting that it may not have an essential role in subviral 
particle assembly in EIAV. This observation is in contrast to 
cysteine residues 198 and 218, which appear to form an 
intramolecular disulfide bond in p26. Examination of the 
sequence of p26 (Figure 22), indicates that this disulfide 
bond results in the formation of a loop at the carboxyl­
terminus of the protein. While it is not possible to speculate 
as to the importance of this bond in the formation of subviral 
core particles, it is of interest to note that both of the 
cysteine residues involved in forming this bond are conserved 
in p24 (Figure 22). This conservation would appear to suggest 
that this bond could be an essential feature of lentiviral 
major core proteins. 
The role of this disulfide bond in the structure of p26 
was investigated using both native and reduced and carboxyl­
methylated p26 in circular dichroism, fluorescence and 
fluorescence quenching studies. Overall, it was demonstrated 
that reduction of the bond caused significant perturbation in 
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the structure of the protein. 
The circular dichroism data for the two forms of the 
protein suggests that there is significant difference in the 
amount of beta-turn structure in the two proteins. While the 
native protein has around 10% beta-turn, the reduced/carboxyl­
methylated protein does not have any (Figure 31 and Table 7). 
One plausible interpretation of these data is that the 
intramolecular disulfide bond stabilizes a beta-turn or loop 
structure at the carboxyl-terminus of the protein. The fact 
that the two linked cysteine residues are separated by just 20 
amino acids, representing approximately 10% of the total 
sequence, suggests that this is indeed a possibility. 
However, it should be noted that the beta-turn motif 
contributes minimally to the overall nature of a CD 
spectrum, and therefore CD is not an accurate technique for 
beta-turn estimation. 
Fluorescence and fluorescence quenching data indicate 
that the environment of the tryptophan residues of p26 (Trp23, 
81, 132) is influenced by the presence of the disulfide bond 
connecting cysteine residues 198 and 218 (Figures 32 & 33). 
This is despite the fact that the closest tryptophan is 
located over 60 amino acids away from either of the two 
cysteine residues. Therefore, this suggests that the 
influences of the disulfide upon the conformation of p26 are 
not limited to the region of the protein in the vicinity of 
the bond, rather, it would appear to have an influence on the 
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global structure of p26. 
The role of the intramolecular disulfide bond of p26 in 
the formation of subviral particles will be an interesting 
area of study. It is tempting to speculate, due to the 
apparent conservation of this disulfide bond, that it serves 
an essential role in the assembly of subviral particles. 
Since subviral particles have not been successfully 
assembled in vitro, an in vivo system would probably be 
necessary for studying the role of the intramolecular 
disulfide bond of p26 on subviral particle assembly. A recent 
report by McGuire and coworkers (1994) described the 
successful expression of subviral EIAV particles in equine 
kidney cells infected with vaccinia viruses expressing the 
EIAV gag gene. This would appear to be an excellent system for 
studying the role of this intramolecular disulfide bond in the 
in vivo assembly of subviral particles. Their reports showed 
that the Gag precursor protein (p55), when expressed in the 
absence of other EIAV proteins, is able to assemble into 
subviral particles. However, the final processing of the 
precursor does require the co-expression of the viral 
protease, a product of the proteolytic processing of the Pol 
precursor (McGuire et al., 1994). In addition to an in vivo 
system for studying particle formation, a mutated form of p26 
would be necessary to undertake such studies. Specifically, 
the p26 mutant would be required to have one of the cysteine 
residues involved in the formation of the intramolecular 
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disulfide bond {Cys198 or Cys218), mutated to a similar amino 
acid (e.g. serine). This could easily be achieved using site­
directed mutagenesis. 
Assuming that the recombinant form of p26 accurately 
mimics the structure of the native protein found in virions, 
and that the intramolecular disulfide bond is relevant in 
vivo, the intramolecular disulfide bond exhibited by p26 must 
form at one of two possible times. Firstly, the disulfide 
could form immediately following translation, when p26 is 
still part of the 55 kDa precursor, indicating that it could 
have a role in the function of p55. The second possibility is 
that the disulfide bond does not form until p55 has been 
processed to yield p26, in which case it may be involved in 
subviral particle assembly. 
If the bond does form in p55, it may be involved in the 
maintenance of p55-Gag in a form which can interact with the 
plasma membrane. If this is the case, and the bond is 
important in the function of the p55 precursor, then subviral 
particle formation would be expected to be affected by a cys 
218 (or cysl98) mutation. Alternatively, the bond could be 
involved in maintaining the p55 precursor in a conformation 
that can be processed effectively by the viral protease. 
Either of these scenarios could be effectively tested using 
the vaccinia virus system of McGuire et al. (1994). 
If the disulfide bond plays a role in the function of 
p55, then subviral particle formation would be expected to be 
affected by the mutation. 
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However, if it is important for 
processing of the gag precursor, then particle formation would 
not be expected to be affected since subviral particle 
formation has been observed in the absence of processing of 
the p55 precursor (McGuire et al., 1994). Rather one would 
predict that the processing of p55 to yield p26 in the 
subviral particles would be affected. This could easily be 
tested by examining the subviral particles for evidence of 
processing by immunoblotting. 
Another possibility is that the bond does not have a role 
in the targeting or processing of p55, but instead forms after 
the proteolytic processing of p55, an event which occurs after 
subviral particle assembly (McGuire et al., 1994). This would 
suggest that the disulfide functions to stabilize the 
formation of p26 containing subviral particles. Since the 
bond is intramolecular, the study of it's role in stabilizing 
p26 monomers does not require particle formation. Therefore, 
an in vitro technique such as differential scanning 
calorimetry (D.S.C.), could be used to study this. 
The recent appreciation of the importance of lentiviral 
Gag proteins in the assembly of infectious viral particles has 
led to new approaches to the development of anti-viral 
therapies and vaccines. Interfering with the Gag-mediated 
budding of viral particles, an essential feature of the viral 
lifecycle, has been proposed as a therapy for lentiviral 
infections. One approach which has shown some degree of 
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promise as a future therapy involves the mutation of HIV-1 Gag 
protein such that it can no longer form sub-viral particles 
(Trona, et a1., 1989). The mutant Gag protein, when co­
expressed with wild-type Gag, is able to exert a dominant 
interference 
decrease in 
on normal particle assembly, 
the amount of infectious 
resulting in a 
virus produced. 
Confirmation of an essential role for the intramolecular 
disulfide bridge in p26, and possibly p24 of HIV-1, could 
provide another mechanism for interfering with subviral 
particle assembly in vivo. It is envisaged that this type of 
treatment, via gene therapy, could function by decreasing the 
amount of infectious virus produced by the host, and so slow 
the development of the disease. This type of approach to 
lentiviral therapy highlights the need for a greater 
understanding of the structure and function of lentiviral Gag 
proteins. 
The structure of Gag proteins also has important 
implications in lentiviral vaccine development. One of the 
most promising vaccines for targeting lentiviral infections 
has been immunization with whole-killed virus. Unfortunately, 
ethical concerns are certain to prevent this kind of approach 
to human vaccine development. However, the apparent 
effectiveness of whole-killed virus preparations, tied to the 
disappointing results attained with individual proteins, has 
accelerated the development of a 'pseudovirus' approach to 
vaccine development. In these systems the viral genome is 
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mutated to render it non-infectious, and the viral structural 
genes (pol, env, and gag) are expressed from heterologous 
promoters. The intent of these systems is to create virus 
particles, which while harmless, contain the full complement 
of structural antigens. The priming of the host's immune 
system to antigens which would be presented in an analogous 
manner to infection is believed to be far superior to 
immunization with individual viral antigens. An additional 
feature of this type of vaccine is that the structural 
antigens can be engineered to enhance their immunogenicity and 
decrease immunosuppressive properties (Haynes et al., 1991). 
The fact that Gag proteins contain large regions of sequence 
which are dispensable for sub-viral particle formation means 
that additional copies of protective or virus neutralizing 
epitopes can be engineered into the Gag protein sequence 
(Wills and craven, 1991). 
Our ability to crystalize p26 represents the first report 
of this being achieved for a major lentiviral core protein in 
the absence of other proteins. It should be noted that a 1990 
paper reported the co-crystallization of p24, the major core 
protein of HIV-1, with an Fab antibody fragment (Prongay et 
al., 1990). However, the crystal structure of p24 has not been 
published, suggesting that this approach may have not 
generated crystals which were suitable for X-ray diffraction. 
In this study, the maximum diameter of the crystal grown 
was approximately 0.1mm, which is slightly smaller than 
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required for X-ray diffraction. One possible explanation for 
our inability to grow crystals beyond O.lmm diameter could be 
heterogeneity in the purity in the protein. Accordingly, we 
developed a more rapid purification procedure for p26 (method 
2), with the rationale that reducing the exposure time of the 
protein to cellular proteases may increase the homogeneity of 
the preparation, and in the process afford the growth of 
larger crystals. Interestingly, the proteolytic cleavage of 
p26 observed in method 1 apppeared to facilitate crystal 
growth rather than inhibit it. The protein purified by 
method two appears to be less soluble than that purified using 
method one, and precipitates when set up to crystallize. We 
propose that this observation could be due to proteolytic 
cleavage of the crystallizable material during purification. 
Because method two is a more rapid purification scheme, and 
lacks the hydroxyapatite step, it is plausible that p26 
purified in this manner does not get cleaved. Analysis of the 
sequence of p26 at it's carboxyl-terminus reveals a very 
hydrophobic stretch of amino acids with the following 
sequence, MMLLAKAL. Seven of the eight amino acids in this 
stretch are hydrophobic, suggesting that if they are not 
cleaved from p26, they may function to decrease the solubility 
of the protein, which has been observed. Accordingly we have 
created a truncated form of p26 which ends at Lys227, the 
amino acid which precedes the hydrophobic tail. This clone 
directs the expression of a 224 amino acid version of p26, and 
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should provide a more homogenous source of truncated protein 
than that produced by the proteolytic cleavage of p26. 
Investigations are currently underway to assess the ability of 
this protein to crystallize, and specifically whether it can 
be used to grow larger crystals than those which have been 
grown to date. 
A knowledge of the 3-dimensional structure of capsid 
proteins provides important structural information which 
assists in understanding how the structure of the protein is 
involved in its functionality, which is accepted as being 
essential for infectivity. Such structural information could 
ultimately be exploited in aiding the design of anti-viral 
agents for blocking capsid assembly /disassembly. This approach 
has been shown to be an effective therapy in targeting human 
rhinoviruses. In these studies, a series of hydrophobic 
organic compounds which bind to a hydrophobic pocket in the 
capsid were developed and shown to impart stability on the 
assembled capsids (Smith et a1., 1986). This in turn prevents 
disassembly of the capsids, blocking virus 'uncoating', an 
essential stage in the viral lifecycle; further, it was also 
shown that the compounds inhibit receptor binding. A similar 
approach has been proposed for targeting HIV, however no 
lentiviral capsid structures have been solved to date. 
The in vitro study of viral core assembly for HIV-1 has 
been approached by Ehrlich and co-workers using recombinant 
p24 purified from E.coli (Ehrlich et al., 1990). They have 
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shown that in vitro, recombinant core protein assembled into 
long rod-like structures (Ehrlich et al., 1992). Although 
these structures do not mimic the cone-shaped capsid seen in 
vivo, the data does demonstrate an intrinsic ability of p24 to 
form stable, oligomeric structures. Self-assembly appears to 
be dependent on protein concentration, pH and ionic strength 
(Ehrlich et al., 1992). Further, it has been shown using 
analytical affinity chromatography (AAC) that p24 can 
reversibly form dimers in vitro (Rose s. et al., 1992). 
We are currently investigating these observations with 
p26 to see if it too is also able to self assemble into 
oligomeric structures, although we have no evidence of this at 
the present time. Ultimately, our findings should help to 
determine whether such 'spontaneous oligomerization' is a 
conserved feature of lentiviral core proteins. If it is, 
it would provide a valuable 'in vitro' system for evaluating 
the ability of drugs to stabilize/destabilize core protein 
structures; such interactions could be studied using a variety 
of biophysical approaches. However, recent observations made 
with EIAV indicated that the p55 Gag precursor, and not 
processed p26, initially forms subviral particles in vivo 
(McGuire, et al., 1994). This would suggest that in vitro 
studies of core particle assembly may require unprocessed Gag 
precursors instead of just the major core protein. This 
observation may help to explain why previous in vitro studies 
of core particle assembly for p24 do not mimic the events 
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observed in vivo. 
The inability of lentiviral core proteins to self­
assemble in vitro into the cone-shaped capsids seen in vivo 
indeed suggests that other factors, including other viral 
proteins, may be important players in the assembly process. In 
HIV-1, the viral infectivity factor (Vif) appears to be a 
candidate for a role in nucleocapsid assembly. It had 
previously been demonstrated that Vif increases viral 
infectivity at the time of virus production, most probably by 
affecting viral protein processing, virus assembly, or virus 
maturation. (Gabuzda et al., 1992; Blanc et al., 1993; Sakai 
et al., 1993). Recently, it has been reported that the vif 
gene product may play a role in packaging of the core of HIV-1 
(Hoglund et al., 1994). In the absence of Vif, the majority of 
virus particles did not exhibit the normal dense, cone-shaped 
core structure. Instead they appeared as heterogeneous, 
irregular structures. The mechanism by which Vif exerts its 
effect on nucleocapsid assembly is not fully understood; 
however, the recent observation that Vif is predominantly a 
cytoplasmic protein associated with the cytoplasmic side of 
the plasma membrane has lead some to suggest that Vif may 
play a role during the final stages of virion assembly at the 
plasma membrane (Goncalves et al., 1994). 
Another interesting observation regarding the vif gene 
product was recently reported by Ma and coworkers ( 19 9 4) . 
They identified a pair of cysteine residues in the vif gene of 
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HIV-1, which are conserved among the animal lentiviruses, 
which appear to serve a critical role in the function of the 
virus. When the cysteine residues in the full-length HIV-1 
genome were mutated to leucines, it was demonstrated that the 
virions adopted a vif- phenotype. The vif- phenotype was 
subsequently abolished by complementation with a Vif 
expression vector (Ma et al., 1994). These observations 
suggested that the pair of cysteine residues, which could 
function by forming a disulfide bond, were critical for viral 
function and infectivity. 
Like the analogous protein in HIV (p24), p26 is a highly 
immunogenic protein which is very highly conserved among 
different viral isolates. For this reason, antibody responses 
to it form the basis of diagnostic assay for determining 
infection. The standard assay for determining EIAV infection 
in horses is the 'Coggins Test' which was introduced in the 
early 1970's (Coggins and Lombard, 1970). This assay takes 
the form of an agar gel immunodiffusion reaction, or 
oucterlony, and detects antibodies to p26 which is isolated 
from cell cultures infected with the EIA virus. Despite the 
obvious shortfalls of an immunodiffusion reaction for 
diagnostic purposes, it remains the most widely used 
diagnostic tool and is regarded as the most reliable assay 
currently available. 
Using recombinant p26 from E.coli, we have developed a 
rapid, sensitive and highly accurate sandwich ELISA for 
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detecting anti-p26 antibodies in sera. The assay takes just 
1 hour to complete and has successfully identified all EIAV 
positive samples tested to date. Most notably it passed a 
'blind' test from the National Veterinary Service Labs (Ames, 
Iowa); successfully identifying 19 positive sera, of varying 
antibody titre, and 11 negative sera. 
An ELISA such as the one described here has many 
potential advantages over an immunodiffusion reaction. The 
first is the speed with which the reaction can be conducted (1 
hour), in comparison to the 'Coggins' Test' which takes 6-12 
hours. A second advantage is the ease with which the result of 
the test, a colorometric reaction, can be interpreted. 
Further, the assay detects antibodies to p26, a highly 
conserved and immunogenic protein, which has formed the basis 
of the longstanding 'Coggins' test. 
One potential drawback of an ELISA is the necessity for 
diluting serum samples prior to testing, a step which is 
essential when using anti-antibody conjugates for detecting 
antibody. However, in our ELISA this problem was circumvented 
by making a p26-peroxidase conjugate for detecting captured 
antibody. It is inferred that only one of the Fab portions of 
the antibody is utilized in binding the antibody to the p26 
immobilized on the plate, leaving a second Fab binding site 
exposed. It is this site which binds the p26-peroxidase 
conjugate, allowing detection of bound antibody. Because the 
p26-peroxidase does not have an affinity for the constant 
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regions of immunoglobulin molecules, unlike anti-antibody 
conjugates, background reactivity is not a concern, even when 
using undiluted serum. One of the few potential problem with 
such a 'sandwich ELISA' is the possible loss in sensitivity 
due to the binding of both of the Fab sites on an antibody to 
the immobilized p26. This does not appear to be a major 
concern since all positive sera have been correctly identified 
so far. However, it may be possible to increase the 
sensi ti vi ty of the assay still further by elevating the 
relative excess of antibody over immobilized antigen, and 
therefore reduce the possibility of both Fab sites on the 
antibody interacting with the immobilized p26. This could be 
approached by reducing the amount of p26 coated to the 
microtitre wells. 
It is envisaged that ultimately the assay could be 
modified to adopt the form of a 'dip-stick' reaction. This 
type of assay, which forms the basis of current pregnancy 
tests, can be conducted in minutes, without the need for any 
laboratory equipment or expertise. Because this virus is a 
worldwide concern, the market for such a simple and rapid 
diagnostic test would be very significant. 
A recombinant source of p26 protein will also permit 
investigation of the immunological properties of this protein. 
The sequence homology of the MHR with core proteins from other 
retroviral core proteins has led to speculation that this 
sequence may harbor an inter-species cross-reactive 
determinant (Grund et al., 1994; Wills and Craven, 
Recent attempts to precisely identify the site of 
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1991}. 
cross-
reactivity using a panel of overlapping synthetic peptides 
were unsuccessful, although the cross-reactive antibodies were 
shown to be specific for the carboxyl-terminal 83 residues of 
p26 (153-235) (Grund et al., 1994). The inability to precisely 
localize this epitope was presumed to indicate that the cross­
reactive epitope of p26 is conformation-dependent, and 
therefore not mimicked by short synthetic peptides. Mutational 
analysis of p26, by substitution of amino acids within the 
MHR, would certainly enable accurate mapping of the cross­
reactive epitope. 
In this report we emphasize the tremendous potential of 
the animal lentiviruses to serve as models for understanding 
this important family of viruses, which includes the human 
immunodeficiency virus. Clearly a recombinant source of p26 
from EIAV has important applications in a variety of 
structural, functional and immunological studies. In light of 
the conserved nature of the lentiviral major core proteins, it 
is envisaged that other major core proteins from other members 
of the Lentiviridae, particularly the antigenically related 
proteins from FIV and BIV, could be cloned, expressed, 
purified, and studied in the manner described here for p26. 
A recombinant source of BIV and FIV core protein would also 
permit the development of a sandwich ELISA, analogous to the 
one described here for EIAV, for commercial use as a 
176 
diagnostic assay. 
CONCLUSIONS 
The suitability of p26, the major core protein from 
equine infectious anaemia virus (EIAV), to serve as a model 
for understanding the structure and function of lentiviral 
core proteins was studied. The protein was expressed, using 
an E.coli expression system, and purified in sufficient 
quantities to allow structural studies to be made. 
Circular dichroism spectroscopy revealed that p2 6 has the 
following assignment of secondary structure; 40% alpha helix, 
22% beta sheet, 10% beta turn and 28% random coil. The high 
degree of alpha helical content of p26 was in agreement with 
the predicted values acquired using the method of Chou and 
Fasmann (46% alpha helix). However, these results contrasted 
to the proposed structural features of another lentiviral 
core protein, p24 from HIV, which is predicted to be comprised 
predominantly of beta structure. This is despite the fact that 
these two core proteins share 55% amino acid similarity. 
It was determined, using a combination of site-directed 
mutagenesis and chemical modification, that p26 contains an 
intramolecular disulfide bridge connecting Cys198 and Cys218, 
and a single free cysteine (Cys48). Further, it was 
demonstrated by fluorescence studies that the integrity of the 
177 
178 
disulfide bond affects the global structure of the protein. 
The presence of this pair of cysteine residues in p24 of HIV-1 
suggests that this disulfide bond may have a conserved role in 
the function of lentiviral core proteins, and may be essential 
in the lifecycle of these viruses. 
A sandwich ELISA was developed for measuring anti-p26 
antibodies in sera, and was evaluated as a diagnostic tool for 
detecting EIAV infection. The assay appears to be extremely 
reliable for detecting infected sera, and exhibits extremely 
low background reactivities with EIAV negative sera. 
Accordingly, the interpretation of the data generated using 
this test would appear to be simple and unambiguous. 
The expression system and purification procedure 
developed for EIAV core protein may be useful for producing 
milligram-gram quantities of other lentiviral core proteins 
for structure, function and immunological studies. It is 
envisaged that this could be extended to include the 
development of marketable diagnostic ELISA's for other animal 
lentiviruses such as feline immunodeficiency virus (FIV). 
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